                         SEQUENCE LISTING

<110>  Nascient Limited
 
<120>  Immunoassay for detection and monitoring of inflammatory responses

<130>  P000169_WO

<160>  210   

<170>  PatentIn version 3.5

<210>  1
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 2A5 VH CDR1

<400>  1

Glu Leu Ser Met His 
1               5   


<210>  2
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 2A5 VH CDR2

<400>  2

Gly Phe Asp Pro Glu Asp Gly Glu Thr Ile Tyr Ala Gln Lys Phe Gln 
1               5                   10                  15      


Gly 
    


<210>  3
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 2A5 VH CDR3

<400>  3

Ala Gln Lys Glu Thr Tyr Ala Leu Thr Tyr 
1               5                   10  


<210>  4
<211>  119
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 2A5 VH amino acid sequence

<400>  4

Glu Val Arg Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Thr Glu Leu 
            20                  25                  30          


Ser Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Gly Phe Asp Pro Glu Asp Gly Glu Thr Ile Tyr Ala Gln Lys Phe 
    50                  55                  60                  


Gln Gly Arg Val Thr Met Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Thr Ala Gln Lys Glu Thr Tyr Ala Leu Thr Tyr Trp Gly Gln Gly 
            100                 105                 110         


Thr Leu Val Thr Val Ser Ser 
        115                 


<210>  5
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 2A5 VL CDR1

<400>  5

Arg Ala Ser Gln Tyr Ile Gln Gly Phe Leu Asn 
1               5                   10      


<210>  6
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 2A5 VL CDR2

<400>  6

Ala Ala Ser Thr Leu Gln Asp 
1               5           


<210>  7
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 2A5 VL CDR3

<400>  7

Gln Gln Ser Tyr Ser Thr Pro Trp Thr 
1               5                   


<210>  8
<211>  108
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 2A5 VL amino acid sequence

<400>  8

Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Pro Thr Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Tyr Ile Gln Gly Phe 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Tyr Ala Ala Ser Thr Leu Gln Asp Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Tyr Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Trp 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg 
            100                 105             


<210>  9
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody B12 VH CDR1

<400>  9

Asp Tyr Ala Met His 
1               5   


<210>  10
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody B12 VH CDR2

<400>  10

Gly Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys 
1               5                   10                  15      


Gly 
    


<210>  11
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody B12 VH CDR3

<400>  11

Asp Ile Ser Ala Val Pro Asp Thr Phe Asp Ile 
1               5                   10      


<210>  12
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody B12 VH amino acid sequence

<400>  12

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr 
            20                  25                  30          


Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ser Gly Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys 
                85                  90                  95      


Ala Lys Asp Ile Ser Ala Val Pro Asp Thr Phe Asp Ile Trp Gly Gln 
            100                 105                 110         


Gly Thr Met Val Thr Val Ser Ser 
        115                 120 


<210>  13
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody B12 VL CDR2

<400>  13

Asp Ala Ser Asn Leu Glu Thr 
1               5           


<210>  14
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody B12 VL CDR3

<400>  14

Gln Gln Ser Tyr Ser Thr Pro Gln Thr 
1               5                   


<210>  15
<211>  108
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody B12 VL amino acid sequence

<400>  15

Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Pro Thr Pro Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Tyr Ile Gln Gly Phe 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Gln 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Asp Ile Lys Arg 
            100                 105             


<210>  16
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody D8 VH CDR1

<400>  16

Ser Tyr Gly Ile Ser 
1               5   


<210>  17
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody D8 VH CDR2

<400>  17

Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Leu Gln 
1               5                   10                  15      


Gly 
    


<210>  18
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody D8 VH CDR3

<400>  18

Asn Gln Asp Ser Ser Ser Asp Tyr 
1               5               


<210>  19
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody D8 VH amino acid sequence

<400>  19

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 
            20                  25                  30          


Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Leu 
    50                  55                  60                  


Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Asn Gln Asp Ser Ser Ser Asp Tyr Trp Gly Gln Gly Thr Leu 
            100                 105                 110         


Val Thr Val Ser Ser 
        115         


<210>  20
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody D8 VL CDR3

<400>  20

Gln Gln Ser Tyr Ser Thr Leu Gln Thr 
1               5                   


<210>  21
<211>  108
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody D8 VL amino acid sequence

<400>  21

Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Pro Thr Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Tyr Ile Gln Gly Phe 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Leu Gln 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Asp Ile Lys Arg 
            100                 105             


<210>  22
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody F3 VH CDR1

<400>  22

Ser Tyr Gly Met His 
1               5   


<210>  23
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody F3 VH CDR2

<400>  23

Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys 
1               5                   10                  15      


Gly 
    


<210>  24
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody F3 VH CDR3

<400>  24

Glu Gly Tyr Asp Gln Leu Phe Ser Ala Glu Ser Asn Ala Phe Asp Ile 
1               5                   10                  15      


<210>  25
<211>  125
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody F3 VH amino acid sequence

<400>  25

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Gly Asn Ser Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Lys Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Glu Gly Tyr Asp Gln Leu Phe Ser Ala Glu Ser Asn Ala Phe 
            100                 105                 110         


Asp Ile Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 
        115                 120                 125 


<210>  26
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody F3 VL CDR1

<400>  26

Thr Arg Ser Ser Gly Ser Ile Ala Ser Tyr Phe Val Gln 
1               5                   10              


<210>  27
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody F3 VL CDR2

<400>  27

Glu Asp Asn Gln Arg Pro Ser 
1               5           


<210>  28
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody F3 VL CDR3

<400>  28

Gln Ser Tyr Asp Ser Ser Asn Trp Val 
1               5                   


<210>  29
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody F3 VL amino acid sequence

<400>  29

Asn Phe Met Leu Ala Gln Pro His Ser Val Ser Glu Ser Pro Gly Lys 
1               5                   10                  15      


Thr Val Thr Ile Ser Cys Thr Arg Ser Ser Gly Ser Ile Ala Ser Tyr 
            20                  25                  30          


Phe Val Gln Trp Phe Gln Gln Arg Pro Gly Ser Ala Pro Thr Ala Val 
        35                  40                  45              


Ile Tyr Glu Asp Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 
    50                  55                  60                  


Gly Ser Ile Asp Ser Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly 
65                  70                  75                  80  


Leu Lys Thr Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser 
                85                  90                  95      


Ser Asn Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu Gly Gln 
            100                 105                 110         


Pro 
    


<210>  30
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 165_13_B1 (derived from B12) VH CDR3

<400>  30

Val Met Ser Ser Met Glu Asp Ala Phe Asp Ile 
1               5                   10      


<210>  31
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 165_13_B1 (derived from B12) VH amino acid sequence

<400>  31

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr 
            20                  25                  30          


Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ser Gly Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys 
                85                  90                  95      


Ala Lys Val Met Ser Ser Met Glu Asp Ala Phe Asp Ile Trp Gly Gln 
            100                 105                 110         


Gly Thr Met Val Thr Val Ser Ser 
        115                 120 


<210>  32
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 165_13_B6 (derived from B12) VH CDR3

<400>  32

Gly Gln Lys Gly Glu Gly Asp Thr Phe Asp Ile 
1               5                   10      


<210>  33
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 165_13_B6 (derived from B12) VH amino acid sequence

<400>  33

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr 
            20                  25                  30          


Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ser Gly Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys 
                85                  90                  95      


Ala Lys Gly Gln Lys Gly Glu Gly Asp Thr Phe Asp Ile Trp Gly Gln 
            100                 105                 110         


Gly Thr Met Val Thr Val Ser Ser 
        115                 120 


<210>  34
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 165_13_D1 (derived from B12) VH CDR3

<400>  34

Gly Thr Arg Gly Glu Gly Asp Thr Phe Asp Ile 
1               5                   10      


<210>  35
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 165_13_D1 (derived from B12) VH amino acid sequence

<400>  35

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr 
            20                  25                  30          


Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ser Gly Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys 
                85                  90                  95      


Ala Lys Gly Thr Arg Gly Glu Gly Asp Thr Phe Asp Ile Trp Gly Gln 
            100                 105                 110         


Gly Thr Met Val Thr Val Ser Ser 
        115                 120 


<210>  36
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 165_13_C3 (derived from B12) VH CDR3

<400>  36

Ser Tyr Gln Ser Asp Glu Asp Ala Phe Asp Ile 
1               5                   10      


<210>  37
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 165_13_C3 (derived from B12) VH amino acid sequence

<400>  37

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr 
            20                  25                  30          


Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ser Gly Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys 
                85                  90                  95      


Ala Lys Ser Tyr Gln Ser Asp Glu Asp Ala Phe Asp Ile Trp Gly Gln 
            100                 105                 110         


Gly Thr Met Val Thr Val Ser Ser 
        115                 120 


<210>  38
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 165_13_D4 (derived from B12) VH CDR3

<400>  38

Gly Thr Val Gly Glu Gly Asp Thr Phe Asp Ile 
1               5                   10      


<210>  39
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 165_13_D4 (derived from B12) VH amino acid sequence

<400>  39

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr 
            20                  25                  30          


Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ser Gly Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys 
                85                  90                  95      


Ala Lys Gly Thr Val Gly Glu Gly Asp Thr Phe Asp Ile Trp Gly Gln 
            100                 105                 110         


Gly Thr Met Val Thr Val Ser Ser 
        115                 120 


<210>  40
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 165_13_A4 (derived from B12) VH CDR3

<400>  40

Asp Lys Tyr Pro Val Leu Asp Thr Phe Asp Ile 
1               5                   10      


<210>  41
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 165_13_A4 (derived from B12) VH amino acid sequence

<400>  41

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr 
            20                  25                  30          


Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ser Gly Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys 
                85                  90                  95      


Ala Lys Asp Lys Tyr Pro Val Leu Asp Thr Phe Asp Ile Trp Gly Gln 
            100                 105                 110         


Gly Thr Met Val Thr Val Ser Ser 
        115                 120 


<210>  42
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 165_13_B3 (derived from B12) VH CDR3

<400>  42

Ala Leu Ala Arg Gly His Asp Thr Phe Asp Ile 
1               5                   10      


<210>  43
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 165_13_B3 (derived from B12) VH amino acid sequence

<400>  43

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr 
            20                  25                  30          


Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ser Gly Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys 
                85                  90                  95      


Ala Lys Ala Leu Ala Arg Gly His Asp Thr Phe Asp Ile Trp Gly Gln 
            100                 105                 110         


Gly Thr Met Val Thr Val Ser Ser 
        115                 120 


<210>  44
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 165_13_E1 (derived from B12) VH CDR3

<400>  44

Asp Ile Ser Ala Val Met Asp Val Pro Gln Thr 
1               5                   10      


<210>  45
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 165_13_E1 (derived from B12) VH amino acid sequence

<400>  45

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr 
            20                  25                  30          


Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ser Gly Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys 
                85                  90                  95      


Ala Lys Asp Ile Ser Ala Val Met Asp Val Pro Gln Thr Trp Gly Gln 
            100                 105                 110         


Gly Thr Met Val Thr Val Ser Ser 
        115                 120 


<210>  46
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 180_11_F5 (derived from B12) VH CDR3

<400>  46

Val Met Arg Thr Gly Leu Asp Thr Phe Asp Ile 
1               5                   10      


<210>  47
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 180_11_F5 (derived from B12) VH amino acid sequence

<400>  47

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr 
            20                  25                  30          


Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ser Gly Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys 
                85                  90                  95      


Ala Lys Val Met Arg Thr Gly Leu Asp Thr Phe Asp Ile Trp Gly Gln 
            100                 105                 110         


Gly Thr Met Val Thr Val Ser Ser 
        115                 120 


<210>  48
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 160_01_E3 (derived from 2A5) VH CDR3

<400>  48

Gln Arg Tyr Val Trp Glu Ala Leu Thr Tyr 
1               5                   10  


<210>  49
<211>  119
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 160_01_E3 (derived from 2A5) VH amino acid sequence

<400>  49

Glu Val Arg Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Thr Glu Leu 
            20                  25                  30          


Ser Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Gly Phe Asp Pro Glu Asp Gly Glu Thr Ile Tyr Ala Gln Lys Phe 
    50                  55                  60                  


Gln Gly Arg Val Thr Met Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Thr Gln Arg Tyr Val Trp Glu Ala Leu Thr Tyr Trp Gly Gln Gly 
            100                 105                 110         


Thr Leu Val Thr Val Ser Ser 
        115                 


<210>  50
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 160_01_D6 (derived from 2A5) VH CDR3

<400>  50

Ala Gln Ala Asp Pro His Leu Phe Thr Tyr 
1               5                   10  


<210>  51
<211>  119
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 160_01_D6 (derived from 2A5) VH amino acid sequence

<400>  51

Glu Val Arg Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Thr Glu Leu 
            20                  25                  30          


Ser Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Gly Phe Asp Pro Glu Asp Gly Glu Thr Ile Tyr Ala Gln Lys Phe 
    50                  55                  60                  


Gln Gly Arg Val Thr Met Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Thr Ala Gln Ala Asp Pro His Leu Phe Thr Tyr Trp Gly Gln Gly 
            100                 105                 110         


Thr Leu Val Thr Val Ser Ser 
        115                 


<210>  52
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 160_01_H4 (derived from 2A5) VH CDR3

<400>  52

Gly Arg Phe Val Trp Glu Ala Leu Thr Tyr 
1               5                   10  


<210>  53
<211>  119
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 160_01_H4 (derived from 2A5) VH amino acid sequence

<400>  53

Glu Val Arg Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Thr Glu Leu 
            20                  25                  30          


Ser Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Gly Phe Asp Pro Glu Asp Gly Glu Thr Ile Tyr Ala Gln Lys Phe 
    50                  55                  60                  


Gln Gly Arg Val Thr Met Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Thr Gly Arg Phe Val Trp Glu Ala Leu Thr Tyr Trp Gly Gln Gly 
            100                 105                 110         


Thr Leu Val Thr Val Ser Ser 
        115                 


<210>  54
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 160_01_A4 (derived from 2A5) VH CDR3

<400>  54

Ala Gln Lys Glu Thr Leu Gly Asn Ala Ile 
1               5                   10  


<210>  55
<211>  119
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 160_01_A4 (derived from 2A5) VH amino acid sequence

<400>  55

Glu Val Arg Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Thr Glu Leu 
            20                  25                  30          


Ser Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Gly Phe Asp Pro Glu Asp Gly Glu Thr Ile Tyr Ala Gln Lys Phe 
    50                  55                  60                  


Gln Gly Arg Val Thr Met Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Thr Ala Gln Lys Glu Thr Leu Gly Asn Ala Ile Trp Gly Gln Gly 
            100                 105                 110         


Thr Leu Val Thr Val Ser Ser 
        115                 


<210>  56
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 160_01_F1 (derived from 2A5) VH CDR3

<400>  56

Ala Gln Ser Pro Trp Ser Gly Met Thr Tyr 
1               5                   10  


<210>  57
<211>  119
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 160_01_F1 (derived from 2A5) VH amino acid sequence

<400>  57

Glu Val Arg Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Thr Glu Leu 
            20                  25                  30          


Ser Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Gly Phe Asp Pro Glu Asp Gly Glu Thr Ile Tyr Ala Gln Lys Phe 
    50                  55                  60                  


Gln Gly Arg Val Thr Met Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Thr Ala Gln Ser Pro Trp Ser Gly Met Thr Tyr Trp Gly Gln Gly 
            100                 105                 110         


Thr Leu Val Thr Val Ser Ser 
        115                 


<210>  58
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 160_01_G2 (derived from 2A5) VH CDR3

<400>  58

Tyr Thr Leu Asp Asn Met Ala Leu Thr Tyr 
1               5                   10  


<210>  59
<211>  119
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 160_01_G2 (derived from 2A5) VH amino acid sequence

<400>  59

Glu Val Arg Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Thr Glu Leu 
            20                  25                  30          


Ser Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Gly Phe Asp Pro Glu Asp Gly Glu Thr Ile Tyr Ala Gln Lys Phe 
    50                  55                  60                  


Gln Gly Arg Val Thr Met Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Thr Tyr Thr Leu Asp Asn Met Ala Leu Thr Tyr Trp Gly Gln Gly 
            100                 105                 110         


Thr Leu Val Thr Val Ser Ser 
        115                 


<210>  60
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 161_01_F6, also known as 160_01_F6 (derived from 2A5) VH
       CDR3

<400>  60

Ala Gln Lys Glu Asn Ile Ala Asn Arg His 
1               5                   10  


<210>  61
<211>  119
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 161_01_F6, also known as 160_01_F6 (derived from 2A5) VH
       amino acid sequence

<400>  61

Glu Val Arg Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Thr Glu Leu 
            20                  25                  30          


Ser Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Gly Phe Asp Pro Glu Asp Gly Glu Thr Ile Tyr Ala Gln Lys Phe 
    50                  55                  60                  


Gln Gly Arg Val Thr Met Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Thr Ala Gln Lys Glu Asn Ile Ala Asn Arg His Trp Gly Gln Gly 
            100                 105                 110         


Thr Leu Val Thr Val Ser Ser 
        115                 


<210>  62
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 161_01_A12 (derived from 2A5) VH CDR3

<400>  62

Ala Gln Pro Thr Ala Leu Ala Asn Thr Tyr 
1               5                   10  


<210>  63
<211>  119
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 161_01_A12 (derived from 2A5) VH amino acid sequence

<400>  63

Glu Val Arg Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Thr Glu Leu 
            20                  25                  30          


Ser Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Gly Phe Asp Pro Glu Asp Gly Glu Thr Ile Tyr Ala Gln Lys Phe 
    50                  55                  60                  


Gln Gly Arg Val Thr Met Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Thr Ala Gln Pro Thr Ala Leu Ala Asn Thr Tyr Trp Gly Gln Gly 
            100                 105                 110         


Thr Leu Val Thr Val Ser Ser 
        115                 


<210>  64
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 161_01_C09 (derived from 2A5) VH CDR3

<400>  64

Ala Gln Leu Pro Tyr Leu Ala Gln Thr Tyr 
1               5                   10  


<210>  65
<211>  119
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 161_01_C09 (derived from 2A5) VH amino acid sequence

<400>  65

Glu Val Arg Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Thr Glu Leu 
            20                  25                  30          


Ser Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Gly Phe Asp Pro Glu Asp Gly Glu Thr Ile Tyr Ala Gln Lys Phe 
    50                  55                  60                  


Gln Gly Arg Val Thr Met Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Thr Ala Gln Leu Pro Tyr Leu Ala Gln Thr Tyr Trp Gly Gln Gly 
            100                 105                 110         


Thr Leu Val Thr Val Ser Ser 
        115                 


<210>  66
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 161_01_H10 (derived from 2A5) VH CDR3

<400>  66

Ala Gln Pro Val Trp Ala Pro Gly Thr Tyr 
1               5                   10  


<210>  67
<211>  119
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 161_01_H10 (derived from 2A5) VH amino acid sequence

<400>  67

Glu Val Arg Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Thr Glu Leu 
            20                  25                  30          


Ser Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Gly Phe Asp Pro Glu Asp Gly Glu Thr Ile Tyr Ala Gln Lys Phe 
    50                  55                  60                  


Gln Gly Arg Val Thr Met Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Thr Ala Gln Pro Val Trp Ala Pro Gly Thr Tyr Trp Gly Gln Gly 
            100                 105                 110         


Thr Leu Val Thr Val Ser Ser 
        115                 


<210>  68
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 161_01_C11 (derived from 2A5) VH CDR3

<400>  68

Ala Gln Lys Glu Trp Leu Pro Asp Val Thr 
1               5                   10  


<210>  69
<211>  119
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 161_01_C11 (derived from 2A5) VH amino acid sequence

<400>  69

Glu Val Arg Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Thr Glu Leu 
            20                  25                  30          


Ser Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Gly Phe Asp Pro Glu Asp Gly Glu Thr Ile Tyr Ala Gln Lys Phe 
    50                  55                  60                  


Gln Gly Arg Val Thr Met Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Thr Ala Gln Lys Glu Trp Leu Pro Asp Val Thr Trp Gly Gln Gly 
            100                 105                 110         


Thr Leu Val Thr Val Ser Ser 
        115                 


<210>  70
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 162_02_D3 (derived from 2A5) VH CDR3

<400>  70

Ala Gln Ile His Pro Leu Gly Leu Thr Tyr 
1               5                   10  


<210>  71
<211>  119
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 162_02_D3 (derived from 2A5) VH amino acid sequence

<400>  71

Glu Val Arg Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Thr Glu Leu 
            20                  25                  30          


Ser Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Gly Phe Asp Pro Glu Asp Gly Glu Thr Ile Tyr Ala Gln Lys Phe 
    50                  55                  60                  


Gln Gly Arg Val Thr Met Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Thr Ala Gln Ile His Pro Leu Gly Leu Thr Tyr Trp Gly Gln Gly 
            100                 105                 110         


Thr Leu Val Thr Val Ser Ser 
        115                 


<210>  72
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 162_02_C6 (derived from 2A5) VL CDR3

<400>  72

Gln Asn Gln Tyr Ala Gly Pro Trp Thr 
1               5                   


<210>  73
<211>  108
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 162_02_C6 (derived from 2A5) VL amino acid sequence

<400>  73

Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Pro Thr Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Tyr Ile Gln Gly Phe 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Tyr Ala Ala Ser Thr Leu Gln Asp Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Tyr Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn Gln Tyr Ala Gly Pro Trp 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg 
            100                 105             


<210>  74
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 162_02_H5 (derived from 2A5) VL CDR3

<400>  74

Gln Asn Gln Tyr Thr Gly Pro Trp Thr 
1               5                   


<210>  75
<211>  108
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 162_02_H5 (derived from 2A5) VL amino acid sequence

<400>  75

Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Pro Thr Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Tyr Ile Gln Gly Phe 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Tyr Ala Ala Ser Thr Leu Gln Asp Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Tyr Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn Gln Tyr Thr Gly Pro Trp 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg 
            100                 105             


<210>  76
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 162_02_F3 (derived from 2A5) VL CDR3

<400>  76

Gln Asn Gln Tyr Arg Gly Pro Trp Thr 
1               5                   


<210>  77
<211>  108
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 162_02_F3 (derived from 2A5) VL amino acid sequence

<400>  77

Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Pro Thr Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Tyr Ile Gln Gly Phe 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Tyr Ala Ala Ser Thr Leu Gln Asp Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Tyr Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn Gln Tyr Arg Gly Pro Trp 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg 
            100                 105             


<210>  78
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 162_02_C1 (derived from 2A5) VL CDR3

<400>  78

Leu His His Tyr Arg Ala Pro Trp Thr 
1               5                   


<210>  79
<211>  108
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 162_02_C1 (derived from 2A5) VL amino acid sequence

<400>  79

Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Pro Thr Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Tyr Ile Gln Gly Phe 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Tyr Ala Ala Ser Thr Leu Gln Asp Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Tyr Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Leu His His Tyr Arg Ala Pro Trp 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg 
            100                 105             


<210>  80
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 162_02_C2 (derived from 2A5) VL CDR3

<400>  80

Met His His Tyr Arg Ala Pro Trp Thr 
1               5                   


<210>  81
<211>  108
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 162_02_C2 (derived from 2A5) VL amino acid sequence

<400>  81

Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Pro Thr Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Tyr Ile Gln Gly Phe 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Tyr Ala Ala Ser Thr Leu Gln Asp Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Tyr Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Met His His Tyr Arg Ala Pro Trp 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg 
            100                 105             


<210>  82
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 162_02_F4 (derived from 2A5) VL CDR3

<400>  82

Met His His Tyr Arg Ser Pro Trp Thr 
1               5                   


<210>  83
<211>  108
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 162_02_F4 (derived from 2A5) VL amino acid sequence

<400>  83

Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Pro Thr Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Tyr Ile Gln Gly Phe 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Tyr Ala Ala Ser Thr Leu Gln Asp Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Tyr Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Met His His Tyr Arg Ser Pro Trp 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg 
            100                 105             


<210>  84
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 162_02_C3 (derived from 2A5) VL CDR3

<400>  84

Met Gln His Tyr Asp Gly Pro Trp Thr 
1               5                   


<210>  85
<211>  108
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 162_02_C3 (derived from 2A5) VL amino acid sequence

<400>  85

Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Pro Thr Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Tyr Ile Gln Gly Phe 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Tyr Ala Ala Ser Thr Leu Gln Asp Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Tyr Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Met Gln His Tyr Asp Gly Pro Trp 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg 
            100                 105             


<210>  86
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 162_02_E11 (derived from 2A5) VL CDR3

<400>  86

Leu His His Tyr Arg Ser Pro Thr Trp Thr 
1               5                   10  


<210>  87
<211>  109
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 162_02_E11 (derived from 2A5) VL amino acid sequence

<400>  87

Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Pro Thr Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Tyr Ile Gln Gly Phe 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Tyr Ala Ala Ser Thr Leu Gln Asp Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Tyr Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Leu His His Tyr Arg Ser Pro Thr 
                85                  90                  95      


Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg 
            100                 105                 


<210>  88
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 163_02_A12 (derived from 2A5) VL CDR3

<400>  88

Leu His His Tyr Arg Glu Pro Trp Thr 
1               5                   


<210>  89
<211>  108
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 163_02_A12 (derived from 2A5) VL amino acid sequence

<400>  89

Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Pro Thr Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Tyr Ile Gln Gly Phe 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Tyr Ala Ala Ser Thr Leu Gln Asp Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Tyr Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Leu His His Tyr Arg Glu Pro Trp 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg 
            100                 105             


<210>  90
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 163_02_D11 (derived from 2A5) VL CDR3

<400>  90

Leu His His Tyr Lys Ser Pro Trp Thr 
1               5                   


<210>  91
<211>  108
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 163_02_D11 (derived from 2A5) VL amino acid sequence

<400>  91

Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Pro Thr Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Tyr Ile Gln Gly Phe 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Tyr Ala Ala Ser Thr Leu Gln Asp Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Tyr Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Leu His His Tyr Lys Ser Pro Trp 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg 
            100                 105             


<210>  92
<211>  228
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Amino acid sequence of human tenascin-C FBG domain

<400>  92

Ile Gly Leu Leu Tyr Pro Phe Pro Lys Asp Cys Ser Gln Ala Met Leu 
1               5                   10                  15      


Asn Gly Asp Thr Thr Ser Gly Leu Tyr Thr Ile Tyr Leu Asn Gly Asp 
            20                  25                  30          


Lys Ala Glu Ala Leu Glu Val Phe Cys Asp Met Thr Ser Asp Gly Gly 
        35                  40                  45              


Gly Trp Ile Val Phe Leu Arg Arg Lys Asn Gly Arg Glu Asn Phe Tyr 
    50                  55                  60                  


Gln Asn Trp Lys Ala Tyr Ala Ala Gly Phe Gly Asp Arg Arg Glu Glu 
65                  70                  75                  80  


Phe Trp Leu Gly Leu Asp Asn Leu Asn Lys Ile Thr Ala Gln Gly Gln 
                85                  90                  95      


Tyr Glu Leu Arg Val Asp Leu Arg Asp His Gly Glu Thr Ala Phe Ala 
            100                 105                 110         


Val Tyr Asp Lys Phe Ser Val Gly Asp Ala Lys Thr Arg Tyr Lys Leu 
        115                 120                 125             


Lys Val Glu Gly Tyr Ser Gly Thr Ala Gly Asp Ser Met Ala Tyr His 
    130                 135                 140                 


Asn Gly Arg Ser Phe Ser Thr Phe Asp Lys Asp Thr Asp Ser Ala Ile 
145                 150                 155                 160 


Thr Asn Cys Ala Leu Ser Tyr Lys Gly Ala Phe Trp Tyr Arg Asn Cys 
                165                 170                 175     


His Arg Val Asn Leu Met Gly Arg Tyr Gly Asp Asn Asn His Ser Gln 
            180                 185                 190         


Gly Val Asn Trp Phe His Trp Lys Gly His Glu His Ser Ile Gln Phe 
        195                 200                 205             


Ala Glu Met Lys Leu Arg Pro Ser Asn Phe Arg Asn Leu Glu Gly Arg 
    210                 215                 220                 


Arg Lys Arg Ala 
225             


<210>  93
<211>  228
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Amino acid sequence of mouse tenascin-C FBG domain

<400>  93

Ile Gly Leu Leu Tyr Pro Phe Pro Arg Asp Cys Ser Gln Ala Met Leu 
1               5                   10                  15      


Asn Gly Asp Thr Thr Ser Gly Leu Tyr Thr Ile Tyr Ile Asn Gly Asp 
            20                  25                  30          


Lys Thr Gln Ala Leu Glu Val Tyr Cys Asp Met Thr Ser Asp Gly Gly 
        35                  40                  45              


Gly Trp Ile Val Phe Leu Arg Arg Lys Asn Gly Arg Glu Asp Phe Tyr 
    50                  55                  60                  


Arg Asn Trp Lys Ala Tyr Ala Ala Gly Phe Gly Asp Arg Arg Glu Glu 
65                  70                  75                  80  


Phe Trp Leu Gly Leu Asp Asn Leu Ser Lys Ile Thr Ala Gln Gly Gln 
                85                  90                  95      


Tyr Glu Leu Arg Val Asp Leu Gln Asp His Gly Glu Ser Ala Tyr Ala 
            100                 105                 110         


Val Tyr Asp Arg Phe Ser Val Gly Asp Ala Lys Ser Arg Tyr Lys Leu 
        115                 120                 125             


Lys Val Glu Gly Tyr Ser Gly Thr Ala Gly Asp Ser Met Asn Tyr His 
    130                 135                 140                 


Asn Gly Arg Ser Phe Ser Thr Tyr Asp Lys Asp Thr Asp Ser Ala Ile 
145                 150                 155                 160 


Thr Asn Cys Ala Leu Ser Tyr Lys Gly Ala Phe Trp Tyr Lys Asn Cys 
                165                 170                 175     


His Arg Val Asn Leu Met Gly Arg Tyr Gly Asp Asn Asn His Ser Gln 
            180                 185                 190         


Gly Val Asn Trp Phe His Trp Lys Gly His Glu Tyr Ser Ile Gln Phe 
        195                 200                 205             


Ala Glu Met Lys Leu Arg Pro Ser Asn Phe Arg Asn Leu Glu Gly Arg 
    210                 215                 220                 


Arg Lys Arg Ala 
225             


<210>  94
<211>  228
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Amino acid sequence of rat tenascin-C FBG domain

<400>  94

Ile Gly Leu Leu Tyr Pro Phe Pro Arg Asp Cys Ser Gln Ala Met Leu 
1               5                   10                  15      


Asn Gly Asp Thr Thr Ser Gly Leu Tyr Thr Ile Tyr Ile Asn Gly Asp 
            20                  25                  30          


Lys Thr Gln Ala Leu Glu Val Tyr Cys Asp Met Thr Ser Asp Gly Gly 
        35                  40                  45              


Gly Trp Ile Val Phe Leu Arg Arg Lys Asn Gly Arg Glu Asp Phe Tyr 
    50                  55                  60                  


Arg Asn Trp Lys Ala Tyr Ala Thr Gly Phe Gly Asp Arg Arg Glu Glu 
65                  70                  75                  80  


Phe Trp Leu Gly Leu Asp Asn Leu Ser Lys Ile Thr Ala Gln Gly Gln 
                85                  90                  95      


Tyr Glu Leu Arg Val Asp Leu Gln Asp His Gly Glu Ser Ala Tyr Ala 
            100                 105                 110         


Val Tyr Asp Arg Phe Ser Val Gly Asp Ala Lys Ser Arg Tyr Lys Leu 
        115                 120                 125             


Lys Val Glu Gly Tyr Ser Gly Thr Ala Gly Asp Ser Met Asn Tyr His 
    130                 135                 140                 


Asn Gly Arg Ser Phe Ser Thr Tyr Asp Lys Asp Thr Asp Ser Ala Ile 
145                 150                 155                 160 


Thr Asn Cys Ala Leu Ser Tyr Lys Gly Ala Phe Trp Tyr Lys Asn Cys 
                165                 170                 175     


His Arg Val Asn Leu Met Gly Arg Tyr Gly Asp Asn Asn His Ser Gln 
            180                 185                 190         


Gly Val Asn Trp Phe His Trp Lys Gly His Glu Tyr Ser Ile Gln Phe 
        195                 200                 205             


Ala Glu Met Lys Leu Arg Pro Ser Asn Phe Arg Asn Leu Glu Gly Arg 
    210                 215                 220                 


Arg Lys Arg Ala 
225             


<210>  95
<211>  228
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Amino acid sequence of dog tenascin-C FBG domain

<400>  95

Ile Gly Leu Leu Tyr Pro Phe Pro Arg Asp Cys Ser Gln Ala Met Leu 
1               5                   10                  15      


Asn Gly Asp Thr Thr Ser Gly Leu Tyr Thr Ile Tyr Leu Asn Gly Asp 
            20                  25                  30          


Lys Ala Gln Ala Leu Glu Val Tyr Cys Asp Met Thr Ser Asp Gly Gly 
        35                  40                  45              


Gly Trp Ile Val Phe Leu Arg Arg Lys Asn Gly Arg Glu Asp Phe Tyr 
    50                  55                  60                  


Arg Asn Trp Lys Ala Tyr Ala Ala Gly Phe Gly Asp Arg Arg Glu Glu 
65                  70                  75                  80  


Phe Trp Leu Gly Leu Asp Asn Leu His Lys Ile Thr Ala Gln Gly Gln 
                85                  90                  95      


Tyr Glu Leu Arg Val Asp Leu Arg Asp His Gly Lys Thr Ala Tyr Ala 
            100                 105                 110         


Val Tyr Asp Arg Phe Ser Val Gly Asp Ala Lys Thr Arg Tyr Lys Leu 
        115                 120                 125             


Lys Val Glu Gly Tyr Ser Gly Thr Ala Gly Asp Ser Met Ala Tyr His 
    130                 135                 140                 


Asn Gly Arg Ser Phe Ser Thr Phe Asp Lys Asp Thr Asp Ser Ala Ile 
145                 150                 155                 160 


Thr Asn Cys Ala Leu Ser Tyr Lys Gly Ala Phe Trp Tyr Lys Asn Cys 
                165                 170                 175     


His Arg Val Asn Leu Met Gly Arg Tyr Gly Asp Asn Asn His Ser Gln 
            180                 185                 190         


Gly Val Asn Trp Phe His Trp Lys Gly His Glu Tyr Ser Ile Gln Phe 
        195                 200                 205             


Ala Glu Met Lys Leu Arg Pro Ser Asn Phe Arg Asn Leu Glu Gly Arg 
    210                 215                 220                 


Arg Lys Arg Ala 
225             


<210>  96
<211>  227
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Amino acid sequence of human tenascin-R FBG domain

<400>  96

Phe Pro His Pro Gln Asp Cys Ala Gln His Leu Met Asn Gly Asp Thr 
1               5                   10                  15      


Leu Ser Gly Val Tyr Pro Ile Phe Leu Asn Gly Glu Leu Ser Gln Lys 
            20                  25                  30          


Leu Gln Val Tyr Cys Asp Met Thr Thr Asp Gly Gly Gly Trp Ile Val 
        35                  40                  45              


Phe Gln Arg Arg Gln Asn Gly Gln Thr Asp Phe Phe Arg Lys Trp Ala 
    50                  55                  60                  


Asp Tyr Arg Val Gly Phe Gly Asn Val Glu Asp Glu Phe Trp Leu Gly 
65                  70                  75                  80  


Leu Asp Asn Ile His Arg Ile Thr Ser Gln Gly Arg Tyr Glu Leu Arg 
                85                  90                  95      


Val Asp Met Arg Asp Gly Gln Glu Ala Ala Phe Ala Ser Tyr Asp Arg 
            100                 105                 110         


Phe Ser Val Glu Asp Ser Arg Asn Leu Tyr Lys Leu Arg Ile Gly Ser 
        115                 120                 125             


Tyr Asn Gly Thr Ala Gly Asp Ser Leu Ser Tyr His Gln Gly Arg Pro 
    130                 135                 140                 


Phe Ser Thr Glu Asp Arg Asp Asn Asp Val Ala Val Thr Asn Cys Ala 
145                 150                 155                 160 


Met Ser Tyr Lys Gly Ala Trp Trp Tyr Lys Asn Cys His Arg Thr Asn 
                165                 170                 175     


Leu Asn Gly Lys Tyr Gly Glu Ser Arg His Ser Gln Gly Ile Asn Trp 
            180                 185                 190         


Tyr His Trp Lys Gly His Glu Phe Ser Ile Pro Phe Val Glu Met Lys 
        195                 200                 205             


Met Arg Pro Tyr Asn His Arg Leu Met Ala Gly Arg Lys Arg Gln Ser 
    210                 215                 220                 


Leu Gln Phe 
225         


<210>  97
<211>  66
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  F3 VH 3.1 primer


<220>
<221>  misc_feature
<222>  (23)..(24)
<223>  /note="wherein 'n' is A, T, G, or C"

<220>
<221>  misc_feature
<222>  (26)..(27)
<223>  /note="wherein 'n' is A, T, G, or C"

<220>
<221>  misc_feature
<222>  (29)..(30)
<223>  /note="wherein 'n' is A, T, G, or C"

<220>
<221>  misc_feature
<222>  (32)..(33)
<223>  /note="wherein 'n' is A, T, G, or C"

<220>
<221>  misc_feature
<222>  (35)..(36)
<223>  /note="wherein 'n' is A, T, G, or C"

<220>
<221>  misc_feature
<222>  (38)..(39)
<223>  /note="wherein 'n' is A, T, G, or C"

<400>  97
agcattactc tcagcagaaa asnnsnnsnn snnsnnsnnt ctcgcacagt aatacacagc       60

cgtgtc                                                                  66


<210>  98
<211>  67
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  F3 VH 3.2 primer


<220>
<221>  misc_feature
<222>  (26)..(27)
<223>  /note="wherein 'n' is A, T, G, or C"

<220>
<221>  misc_feature
<222>  (29)..(30)
<223>  /note="wherein 'n' is A, T, G, or C"

<220>
<221>  misc_feature
<222>  (32)..(33)
<223>  /note="wherein 'n' is A, T, G, or C"

<220>
<221>  misc_feature
<222>  (35)..(36)
<223>  /note="wherein 'n' is A, T, G, or C"

<220>
<221>  misc_feature
<222>  (38)..(39)
<223>  /note="wherein 'n' is A, T, G, or C"

<220>
<221>  misc_feature
<222>  (41)..(42)
<223>  /note="wherein 'n' is A, T, G, or C"

<400>  98
ctggccccag atatcaaaag cattsnnsnn snnsnnsnns nnttggtcat agccttctct       60

cgcacag                                                                 67


<210>  99
<211>  69
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  F3 VH 3.3 primer


<220>
<221>  misc_feature
<222>  (26)..(27)
<223>  /note="wherein 'n' is A, T, G or C"

<220>
<221>  misc_feature
<222>  (29)..(30)
<223>  /note="wherein 'n' is A, T, G or C"

<220>
<221>  misc_feature
<222>  (32)..(33)
<223>  /note="wherein 'n' is A, T, G or C"

<220>
<221>  misc_feature
<222>  (35)..(36)
<223>  /note="wherein 'n' is A, T, G or C"

<220>
<221>  misc_feature
<222>  (38)..(39)
<223>  /note="wherein 'n' is A, T, G or C"

<220>
<221>  misc_feature
<222>  (41)..(42)
<223>  /note="wherein 'n' is A, T, G or C"

<400>  99
ggtgaccagg gttccctggc cccasnnsnn snnsnnsnns nnctcagcag aaaatagttg       60

gtcatagcc                                                               69


<210>  100
<211>  66
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  F3 VL 3.1 primer


<220>
<221>  misc_feature
<222>  (26)..(27)
<223>  /note="wherein 'n' is A, T, G or C"

<220>
<221>  misc_feature
<222>  (29)..(30)
<223>  /note="wherein 'n' is A, T, G or C"

<220>
<221>  misc_feature
<222>  (32)..(33)
<223>  /note="wherein 'n' is A, T, G or C"

<220>
<221>  misc_feature
<222>  (35)..(36)
<223>  /note="wherein 'n' is A, T, G or C"

<220>
<221>  misc_feature
<222>  (38)..(39)
<223>  /note="wherein 'n' is A, T, G or C"

<220>
<221>  misc_feature
<222>  (41)..(42)
<223>  /note="wherein 'n' is A, T, G or C"

<400>  100
ggtccctccg ccgaacaccc aattsnnsnn snnsnnsnns nnacagtagt agtcagcctc       60

gtcctc                                                                  66


<210>  101
<211>  66
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  F3 VL 3.2 primer


<220>
<221>  misc_feature
<222>  (26)..(27)
<223>  /note="wherein 'n' is A, T, G or C"

<220>
<221>  misc_feature
<222>  (29)..(30)
<223>  /note="wherein 'n' is A, T, G or C"

<220>
<221>  misc_feature
<222>  (32)..(33)
<223>  /note="wherein 'n' is A, T, G or C"

<220>
<221>  misc_feature
<222>  (35)..(36)
<223>  /note="wherein 'n' is A, T, G or C"

<220>
<221>  misc_feature
<222>  (38)..(39)
<223>  /note="wherein 'n' is A, T, G or C"

<220>
<221>  misc_feature
<222>  (41)..(42)
<223>  /note="wherein 'n' is A, T, G or C"

<400>  101
ggtgaccttg gtccctccgc cgaasnnsnn snnsnnsnns nnataagact gacagtagta       60

gtcagc                                                                  66


<210>  102
<211>  70
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  B12 VH 3 primer


<220>
<221>  misc_feature
<222>  (27)..(28)
<223>  /note="wherein 'n' is A, T, G or C"

<220>
<221>  misc_feature
<222>  (30)..(31)
<223>  /note="wherein 'n' is A, T, G or C"

<220>
<221>  misc_feature
<222>  (33)..(34)
<223>  /note="wherein 'n' is A, T, G or C"

<220>
<221>  misc_feature
<222>  (36)..(37)
<223>  /note="wherein 'n' is A, T, G or C"

<220>
<221>  misc_feature
<222>  (39)..(40)
<223>  /note="wherein 'n' is A, T, G or C"

<220>
<221>  misc_feature
<222>  (42)..(43)
<223>  /note="wherein 'n' is A, T, G or C"

<400>  102
cttggcccca gatatcaaaa gtatcsnnsn nsnnsnnsnn snnttttgca cagtaataca       60

aggccgtgtc                                                              70


<210>  103
<211>  67
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  B12 VH 3.2 primer


<220>
<221>  misc_feature
<222>  (26)..(27)
<223>  /note="wherein 'n' is A, T, G or C"

<220>
<221>  misc_feature
<222>  (29)..(30)
<223>  /note="wherein 'n' is A, T, G or C"

<220>
<221>  misc_feature
<222>  (32)..(33)
<223>  /note="wherein 'n' is A, T, G or C"

<220>
<221>  misc_feature
<222>  (35)..(36)
<223>  /note="wherein 'n' is A, T, G or C"

<220>
<221>  misc_feature
<222>  (38)..(39)
<223>  /note="wherein 'n' is A, T, G or C"

<220>
<221>  misc_feature
<222>  (41)..(42)
<223>  /note="wherein 'n' is A, T, G or C"

<400>  103
cattgtccct tggccccaga tatcsnnsnn snnsnnsnns nncgagatat cttttgcaca       60

gtaatac                                                                 67


<210>  104
<211>  67
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  B12 VH 3.3 primer


<220>
<221>  misc_feature
<222>  (26)..(27)
<223>  /note="wherein 'n' is A, T, G or C"

<220>
<221>  misc_feature
<222>  (29)..(30)
<223>  /note="wherein 'n' is A, T, G or C"

<220>
<221>  misc_feature
<222>  (32)..(33)
<223>  /note="wherein 'n' is A, T, G or C"

<220>
<221>  misc_feature
<222>  (35)..(36)
<223>  /note="wherein 'n' is A, T, G or C"

<220>
<221>  misc_feature
<222>  (38)..(39)
<223>  /note="wherein 'n' is A, T, G or C"

<220>
<221>  misc_feature
<222>  (41)..(42)
<223>  /note="wherein 'n' is A, T, G or C"

<400>  104
ggtgaccatt gtcccttggc cccasnnsnn snnsnnsnns nngactgccg agatatcttt       60

tgcacag                                                                 67


<210>  105
<211>  66
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  B12 VL3.1 primer


<220>
<221>  misc_feature
<222>  (26)..(27)
<223>  /note="wherein 'n' is A, T, G or C"

<220>
<221>  misc_feature
<222>  (29)..(30)
<223>  /note="wherein 'n' is A, T, G or C"

<220>
<221>  misc_feature
<222>  (32)..(33)
<223>  /note="wherein 'n' is A, T, G or C"

<220>
<221>  misc_feature
<222>  (35)..(36)
<223>  /note="wherein 'n' is A, T, G or C"

<220>
<221>  misc_feature
<222>  (38)..(39)
<223>  /note="wherein 'n' is A, T, G or C"

<220>
<221>  misc_feature
<222>  (41)..(42)
<223>  /note="wherein 'n' is A, T, G or C"

<400>  105
ggtcccttgg ccgaacgtct gaggsnnsnn snnsnnsnns nnacagtagt aagttgcaaa       60

atcttc                                                                  66


<210>  106
<211>  69
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  B12 VL 3.2 primer


<220>
<221>  misc_feature
<222>  (29)..(30)
<223>  /note="wherein 'n' is A, T, G or C"

<220>
<221>  misc_feature
<222>  (32)..(33)
<223>  /note="wherein 'n' is A, T, G or C"

<220>
<221>  misc_feature
<222>  (35)..(36)
<223>  /note="wherein 'n' is A, T, G or C"

<220>
<221>  misc_feature
<222>  (38)..(39)
<223>  /note="wherein 'n' is A, T, G or C"

<220>
<221>  misc_feature
<222>  (41)..(42)
<223>  /note="wherein 'n' is A, T, G or C"

<220>
<221>  misc_feature
<222>  (44)..(45)
<223>  /note="wherein 'n' is A, T, G or C"

<400>  106
gatatccact ttggtccctt ggccgaasnn snnsnnsnns nnsnnactct gttgacagta       60

gtaagttgc                                                               69


<210>  107
<211>  69
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  2A5 VH 3.1 primer


<220>
<221>  misc_feature
<222>  (29)..(30)
<223>  /note="wherein 'n' is A, T, G or C"

<220>
<221>  misc_feature
<222>  (32)..(33)
<223>  /note="wherein 'n' is A, T, G or C"

<220>
<221>  misc_feature
<222>  (35)..(36)
<223>  /note="wherein 'n' is A, T, G or C"

<220>
<221>  misc_feature
<222>  (38)..(39)
<223>  /note="wherein 'n' is A, T, G or C"

<220>
<221>  misc_feature
<222>  (41)..(42)
<223>  /note="wherein 'n' is A, T, G or C"

<220>
<221>  misc_feature
<222>  (44)..(45)
<223>  /note="wherein 'n' is A, T, G or C"

<400>  107
ggttccctgg ccccagtagg tcaaggcsnn snnsnnsnns nnsnntgttg cacagtaata       60

cacggccgt                                                               69


<210>  108
<211>  66
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  2A5 VH 3.2 primer


<220>
<221>  misc_feature
<222>  (26)..(27)
<223>  /note="wherein 'n' is A, T, G or C"

<220>
<221>  misc_feature
<222>  (29)..(30)
<223>  /note="wherein 'n' is A, T, G or C"

<220>
<221>  misc_feature
<222>  (32)..(33)
<223>  /note="wherein 'n' is A, T, G or C"

<220>
<221>  misc_feature
<222>  (35)..(36)
<223>  /note="wherein 'n' is A, T, G or C"

<220>
<221>  misc_feature
<222>  (38)..(39)
<223>  /note="wherein 'n' is A, T, G or C"

<220>
<221>  misc_feature
<222>  (41)..(42)
<223>  /note="wherein 'n' is A, T, G or C"

<400>  108
cagggttccc tggccccagt aggtsnnsnn snnsnnsnns nnctgggctg ttgcacagta       60

atacac                                                                  66


<210>  109
<211>  66
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  2A5 VH 3.3 primer


<220>
<221>  misc_feature
<222>  (26)..(27)
<223>  /note="wherein 'n' is A, T, G or C"

<220>
<221>  misc_feature
<222>  (29)..(30)
<223>  /note="wherein 'n' is A, T, G or C"

<220>
<221>  misc_feature
<222>  (32)..(33)
<223>  /note="wherein 'n' is A, T, G or C"

<220>
<221>  misc_feature
<222>  (35)..(36)
<223>  /note="wherein 'n' is A, T, G or C"

<220>
<221>  misc_feature
<222>  (38)..(39)
<223>  /note="wherein 'n' is A, T, G or C"

<220>
<221>  misc_feature
<222>  (41)..(42)
<223>  /note="wherein 'n' is A, T, G or C"

<400>  109
ggtgaccagg gttccctggc cccasnnsnn snnsnnsnns nnctctttct gggctgttgc       60

acagta                                                                  66


<210>  110
<211>  66
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  2A5 VL 3.1 primer


<220>
<221>  misc_feature
<222>  (26)..(27)
<223>  /note="wherein 'n' is A, T, G or C"

<220>
<221>  misc_feature
<222>  (29)..(30)
<223>  /note="wherein 'n' is A, T, G or C"

<220>
<221>  misc_feature
<222>  (32)..(33)
<223>  /note="wherein 'n' is A, T, G or C"

<220>
<221>  misc_feature
<222>  (35)..(36)
<223>  /note="wherein 'n' is A, T, G or C"

<220>
<221>  misc_feature
<222>  (38)..(39)
<223>  /note="wherein 'n' is A, T, G or C"

<220>
<221>  misc_feature
<222>  (41)..(42)
<223>  /note="wherein 'n' is A, T, G or C"

<400>  110
ggtcccttgg ccgaacgtcc acggsnnsnn snnsnnsnns nnacagtagt aagttgcaaa       60

atcttc                                                                  66


<210>  111
<211>  66
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  2A5 VL 3.2 primer


<220>
<221>  misc_feature
<222>  (26)..(27)
<223>  /note="wherein 'n' is A, T, G or C"

<220>
<221>  misc_feature
<222>  (29)..(30)
<223>  /note="wherein 'n' is A, T, G or C"

<220>
<221>  misc_feature
<222>  (32)..(33)
<223>  /note="wherein 'n' is A, T, G or C"

<220>
<221>  misc_feature
<222>  (35)..(36)
<223>  /note="wherein 'n' is A, T, G or C"

<220>
<221>  misc_feature
<222>  (38)..(39)
<223>  /note="wherein 'n' is A, T, G or C"

<220>
<221>  misc_feature
<222>  (41)..(42)
<223>  /note="wherein 'n' is A, T, G or C"

<400>  111
ctccaccttg gtcccttggc cgaasnnsnn snnsnnsnns nnactctgtt gacagtagta       60

agttgc                                                                  66


<210>  112
<211>  119
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 2A5 Framework Germlined: VH amino acid sequence

<400>  112

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Thr Glu Leu 
            20                  25                  30          


Ser Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Gly Phe Asp Pro Glu Asp Gly Glu Thr Ile Tyr Ala Gln Lys Phe 
    50                  55                  60                  


Gln Gly Arg Val Thr Met Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Thr Ala Gln Lys Glu Thr Tyr Ala Leu Thr Tyr Trp Gly Gln Gly 
            100                 105                 110         


Thr Leu Val Thr Val Ser Ser 
        115                 


<210>  113
<211>  108
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 2A5 Framework Germlined: VL amino acid sequence

<400>  113

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Tyr Ile Gln Gly Phe 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Trp 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg 
            100                 105             


<210>  114
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 2A5 CDRs changed as a result of the germlined sequence 
       VL CDR2

<400>  114

Ala Ala Ser Ser Leu Gln Ser 
1               5           


<210>  115
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody B12 Framework Germlined: VH amino acid sequence

<400>  115

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr 
            20                  25                  30          


Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ser Gly Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Tyr Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys 
                85                  90                  95      


Ala Lys Asp Ile Ser Ala Val Pro Asp Thr Phe Asp Ile Trp Gly Gln 
            100                 105                 110         


Gly Thr Met Val Thr Val Ser Ser 
        115                 120 


<210>  116
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody B12 CDRs changed as a result of the germlined sequence 
       VH CDR2

<400>  116

Gly Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys 
1               5                   10                  15      


Tyr 
    


<210>  117
<211>  108
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody B12 Framework Germlined: VL amino acid sequence

<400>  117

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Tyr Ile Gln Gly Phe 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Asp Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Gln 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Asp Ile Lys Arg 
            100                 105             


<210>  118
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody B12 CDRs changed as a result of the germlined sequence 
       VL CDR2

<400>  118

Asp Ala Ser Ser Leu Gln Ser 
1               5           


<210>  119
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody D8 Framework Germlined: VH amino acid sequence

<400>  119

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 
            20                  25                  30          


Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Leu 
    50                  55                  60                  


Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Asn Gln Asp Ser Ser Ser Asp Tyr Trp Gly Gln Gly Thr Leu 
            100                 105                 110         


Val Thr Val Ser Ser 
        115         


<210>  120
<211>  108
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody D8 Framework Germlined: VL amino acid sequence

<400>  120

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Tyr Ile Gln Gly Phe 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Asp Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Leu Gln 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg 
            100                 105             


<210>  121
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody D8 CDRs changed as a result of the germlined sequence VL
       CDR2

<400>  121

Asp Ala Ser Ser Leu Gln Ser 
1               5           


<210>  122
<211>  125
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody F3 Framework germlined: VH amino acid sequence

<400>  122

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Glu Gly Tyr Asp Gln Leu Phe Ser Ala Glu Ser Asn Ala Phe 
            100                 105                 110         


Asp Ile Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 
        115                 120                 125 


<210>  123
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody F3 Framework germlined: VL amino acid sequence

<400>  123

Asn Phe Met Leu Thr Gln Pro His Ser Val Ser Glu Ser Pro Gly Lys 
1               5                   10                  15      


Thr Val Thr Ile Ser Cys Thr Arg Ser Ser Gly Ser Ile Ala Ser Tyr 
            20                  25                  30          


Phe Val Gln Trp Tyr Gln Gln Arg Pro Gly Ser Ser Pro Thr Thr Val 
        35                  40                  45              


Ile Tyr Glu Asp Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 
    50                  55                  60                  


Gly Ser Ile Asp Ser Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly 
65                  70                  75                  80  


Leu Lys Thr Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser 
                85                  90                  95      


Ser Asn Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln 
            100                 105                 110         


Pro 
    


<210>  124
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 2A5 VL amino acid sequence

<400>  124

Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Pro Thr Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Tyr Ile Gln Gly Phe 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Tyr Ala Ala Ser Thr Leu Gln Asp Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Tyr Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Trp 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  125
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody B12 VL amino acid sequence

<400>  125

Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Pro Thr Pro Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Tyr Ile Gln Gly Phe 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Gln 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Asp Ile Lys 
            100                 105         


<210>  126
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody D8 VL amino acid sequence

<400>  126

Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Pro Thr Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Tyr Ile Gln Gly Phe 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Leu Gln 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Asp Ile Lys 
            100                 105         


<210>  127
<211>  110
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody F3 VL amino acid sequence

<400>  127

Asn Phe Met Leu Ala Gln Pro His Ser Val Ser Glu Ser Pro Gly Lys 
1               5                   10                  15      


Thr Val Thr Ile Ser Cys Thr Arg Ser Ser Gly Ser Ile Ala Ser Tyr 
            20                  25                  30          


Phe Val Gln Trp Phe Gln Gln Arg Pro Gly Ser Ala Pro Thr Ala Val 
        35                  40                  45              


Ile Tyr Glu Asp Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 
    50                  55                  60                  


Gly Ser Ile Asp Ser Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly 
65                  70                  75                  80  


Leu Lys Thr Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser 
                85                  90                  95      


Ser Asn Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 
            100                 105                 110 


<210>  128
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 162_02_C6 (derived from 2A5) VL amino acid sequence

<400>  128

Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Pro Thr Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Tyr Ile Gln Gly Phe 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Tyr Ala Ala Ser Thr Leu Gln Asp Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Tyr Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn Gln Tyr Ala Gly Pro Trp 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  129
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 162_02_H5 (derived from 2A5) VL amino acid sequence

<400>  129

Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Pro Thr Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Tyr Ile Gln Gly Phe 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Tyr Ala Ala Ser Thr Leu Gln Asp Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Tyr Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn Gln Tyr Thr Gly Pro Trp 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  130
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 162_02_F3 (derived from 2A5) VL amino acid sequence

<400>  130

Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Pro Thr Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Tyr Ile Gln Gly Phe 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Tyr Ala Ala Ser Thr Leu Gln Asp Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Tyr Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn Gln Tyr Arg Gly Pro Trp 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  131
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 162_02_C1 (derived from 2A5) VL amino acid sequence

<400>  131

Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Pro Thr Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Tyr Ile Gln Gly Phe 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Tyr Ala Ala Ser Thr Leu Gln Asp Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Tyr Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Leu His His Tyr Arg Ala Pro Trp 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  132
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 162_02_C2 (derived from 2A5) VL amino acid sequence

<400>  132

Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Pro Thr Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Tyr Ile Gln Gly Phe 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Tyr Ala Ala Ser Thr Leu Gln Asp Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Tyr Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Met His His Tyr Arg Ala Pro Trp 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  133
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 162_02_F4 (derived from 2A5) VL amino acid sequence

<400>  133

Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Pro Thr Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Tyr Ile Gln Gly Phe 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Tyr Ala Ala Ser Thr Leu Gln Asp Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Tyr Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Met His His Tyr Arg Ser Pro Trp 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  134
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 162_02_C3 (derived from 2A5) VL amino acid sequence

<400>  134

Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Pro Thr Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Tyr Ile Gln Gly Phe 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Tyr Ala Ala Ser Thr Leu Gln Asp Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Tyr Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Met Gln His Tyr Asp Gly Pro Trp 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  135
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 162_02_E11 (derived from 2A5) VL CDR3

<400>  135

Leu His His Tyr Arg Ser Pro Trp Thr 
1               5                   


<210>  136
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 162_02_E11 (derived from 2A5) VL amino acid sequence

<400>  136

Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Pro Thr Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Tyr Ile Gln Gly Phe 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Tyr Ala Ala Ser Thr Leu Gln Asp Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Tyr Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Leu His His Tyr Arg Ser Pro Trp 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  137
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 163_02_A12 (derived from 2A5) VL amino acid sequence

<400>  137

Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Pro Thr Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Tyr Ile Gln Gly Phe 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Tyr Ala Ala Ser Thr Leu Gln Asp Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Tyr Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Leu His His Tyr Arg Glu Pro Trp 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  138
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 163_02_D11 (derived from 2A5) VL amino acid sequence

<400>  138

Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Pro Thr Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Tyr Ile Gln Gly Phe 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Tyr Ala Ala Ser Thr Leu Gln Asp Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Tyr Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Leu His His Tyr Lys Ser Pro Trp 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  139
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 2A5 Framework Germlined: VL amino acid sequence

<400>  139

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Tyr Ile Gln Gly Phe 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Trp 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  140
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody B12 Framework Germlined: VL amino acid sequence

<400>  140

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Tyr Ile Gln Gly Phe 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Asp Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Gln 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Asp Ile Lys 
            100                 105         


<210>  141
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody D8 Framework Germlined: VL amino acid sequence

<400>  141

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Tyr Ile Gln Gly Phe 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Asp Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Leu Gln 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  142
<211>  110
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody F3 Framework germlined: VL amino acid sequence

<400>  142

Asn Phe Met Leu Thr Gln Pro His Ser Val Ser Glu Ser Pro Gly Lys 
1               5                   10                  15      


Thr Val Thr Ile Ser Cys Thr Arg Ser Ser Gly Ser Ile Ala Ser Tyr 
            20                  25                  30          


Phe Val Gln Trp Tyr Gln Gln Arg Pro Gly Ser Ser Pro Thr Thr Val 
        35                  40                  45              


Ile Tyr Glu Asp Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 
    50                  55                  60                  


Gly Ser Ile Asp Ser Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly 
65                  70                  75                  80  


Leu Lys Thr Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser 
                85                  90                  95      


Ser Asn Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 
            100                 105                 110 


<210>  143
<211>  446
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IgG4 165_13_C3 (constant region with hinge modification as 
       described in Angal 1993)

<400>  143

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr 
            20                  25                  30          


Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ser Gly Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys 
                85                  90                  95      


Ala Lys Ser Tyr Gln Ser Asp Glu Asp Ala Phe Asp Ile Trp Gly Gln 
            100                 105                 110         


Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 
        115                 120                 125             


Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala 
    130                 135                 140                 


Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 
145                 150                 155                 160 


Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 
                165                 170                 175     


Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 
            180                 185                 190         


Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys 
        195                 200                 205             


Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro 
    210                 215                 220                 


Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val 
225                 230                 235                 240 


Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr 
                245                 250                 255     


Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu 
            260                 265                 270         


Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys 
        275                 280                 285             


Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser 
    290                 295                 300                 


Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys 
305                 310                 315                 320 


Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile 
                325                 330                 335     


Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro 
            340                 345                 350         


Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu 
        355                 360                 365             


Val Lys Gly Phe Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly 
    370                 375                 380                 


Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp 
385                 390                 395                 400 


Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp 
                405                 410                 415     


Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His 
            420                 425                 430         


Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys 
        435                 440                 445     


<210>  144
<211>  23
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Human Tenascin-C TA domain

<400>  144

Gly Val Leu Lys Lys Val Ile Arg His Lys Arg Gln Ser Gly Val Asn 
1               5                   10                  15      


Ala Thr Leu Pro Glu Glu Asn 
            20              


<210>  145
<211>  476
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Human Tenascin-C EGFL domain

<400>  145

Cys Cys Leu Gln Pro Ala Thr Gly Arg Leu Asp Thr Arg Pro Phe Cys 
1               5                   10                  15      


Ser Gly Arg Gly Asn Phe Ser Thr Glu Gly Cys Gly Cys Val Cys Glu 
            20                  25                  30          


Pro Gly Trp Lys Gly Pro Asn Cys Ser Glu Pro Glu Cys Pro Gly Asn 
        35                  40                  45              


Cys His Leu Arg Gly Arg Cys Ile Asp Gly Gln Cys Ile Cys Asp Asp 
    50                  55                  60                  


Gly Phe Thr Gly Glu Asp Cys Ser Gln Leu Ala Cys Pro Ser Asp Cys 
65                  70                  75                  80  


Asn Asp Gln Gly Lys Cys Val Asn Gly Val Cys Ile Cys Phe Glu Gly 
                85                  90                  95      


Tyr Ala Gly Ala Asp Cys Ser Arg Glu Ile Cys Pro Val Pro Cys Ser 
            100                 105                 110         


Glu Glu His Gly Thr Cys Val Asp Gly Leu Cys Val Cys His Asp Gly 
        115                 120                 125             


Phe Ala Gly Asp Asp Cys Asn Lys Pro Leu Cys Leu Asn Asn Cys Tyr 
    130                 135                 140                 


Asn Arg Gly Arg Cys Val Glu Asn Glu Cys Val Cys Asp Glu Gly Phe 
145                 150                 155                 160 


Thr Gly Glu Asp Cys Ser Glu Leu Ile Cys Pro Asn Asp Cys Phe Asp 
                165                 170                 175     


Arg Gly Arg Cys Ile Asn Gly Thr Cys Tyr Cys Glu Glu Gly Phe Thr 
            180                 185                 190         


Gly Glu Asp Cys Gly Lys Pro Thr Cys Pro His Ala Cys His Thr Gln 
        195                 200                 205             


Gly Arg Cys Glu Glu Gly Gln Cys Val Cys Asp Glu Gly Phe Ala Gly 
    210                 215                 220                 


Leu Asp Cys Ser Glu Lys Arg Cys Pro Ala Asp Cys His Asn Arg Gly 
225                 230                 235                 240 


Arg Cys Val Asp Gly Arg Cys Glu Cys Asp Asp Gly Phe Thr Gly Ala 
                245                 250                 255     


Asp Cys Gly Glu Leu Lys Cys Pro Asn Gly Cys Ser Gly His Gly Arg 
            260                 265                 270         


Cys Val Asn Gly Gln Cys Val Cys Asp Glu Gly Tyr Thr Gly Glu Asp 
        275                 280                 285             


Cys Ser Gln Leu Arg Cys Pro Asn Asp Cys His Ser Arg Gly Arg Cys 
    290                 295                 300                 


Val Glu Gly Lys Cys Val Cys Glu Gln Gly Phe Lys Gly Tyr Asp Cys 
305                 310                 315                 320 


Ser Asp Met Ser Cys Pro Asn Asp Cys His Gln His Gly Arg Cys Val 
                325                 330                 335     


Asn Gly Met Cys Val Cys Asp Asp Gly Tyr Thr Gly Glu Asp Cys Arg 
            340                 345                 350         


Asp Arg Gln Cys Pro Arg Asp Cys Ser Asn Arg Gly Leu Cys Val Asp 
        355                 360                 365             


Gly Gln Cys Val Cys Glu Asp Gly Phe Thr Gly Pro Asp Cys Ala Glu 
    370                 375                 380                 


Leu Ser Cys Pro Asn Asp Cys His Gly Gln Gly Arg Cys Val Asn Gly 
385                 390                 395                 400 


Gln Cys Val Cys His Glu Gly Phe Met Gly Lys Asp Cys Lys Glu Gln 
                405                 410                 415     


Arg Cys Pro Ser Asp Cys His Gly Gln Gly Arg Cys Val Asp Gly Gln 
            420                 425                 430         


Cys Ile Cys His Glu Gly Phe Thr Gly Leu Asp Cys Gly Gln His Ser 
        435                 440                 445             


Cys Pro Ser Asp Cys Asn Asn Leu Gly Gln Cys Val Ser Gly Arg Cys 
    450                 455                 460                 


Ile Cys Asn Glu Gly Tyr Ser Gly Glu Asp Cys Ser 
465                 470                 475     


<210>  146
<211>  1352
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Human Tenascin-C FNIII domain

<400>  146

Glu Val Ser Pro Pro Lys Asp Leu Val Val Thr Glu Val Thr Glu Glu 
1               5                   10                  15      


Thr Val Asn Leu Ala Trp Asp Asn Glu Met Arg Val Thr Glu Tyr Leu 
            20                  25                  30          


Val Val Tyr Thr Pro Thr His Glu Gly Gly Leu Glu Met Gln Phe Arg 
        35                  40                  45              


Val Pro Gly Asp Gln Thr Ser Thr Ile Ile Gln Glu Leu Glu Pro Gly 
    50                  55                  60                  


Val Glu Tyr Phe Ile Arg Val Phe Ala Ile Leu Glu Asn Lys Lys Ser 
65                  70                  75                  80  


Ile Pro Val Ser Ala Arg Val Ala Thr Tyr Leu Pro Ala Pro Glu Gly 
                85                  90                  95      


Leu Lys Phe Lys Ser Ile Lys Glu Thr Ser Val Glu Val Glu Trp Asp 
            100                 105                 110         


Pro Leu Asp Ile Ala Phe Glu Thr Trp Glu Ile Ile Phe Arg Asn Met 
        115                 120                 125             


Asn Lys Glu Asp Glu Gly Glu Ile Thr Lys Ser Leu Arg Arg Pro Glu 
    130                 135                 140                 


Thr Ser Tyr Arg Gln Thr Gly Leu Ala Pro Gly Gln Glu Tyr Glu Ile 
145                 150                 155                 160 


Ser Leu His Ile Val Lys Asn Asn Thr Arg Gly Pro Gly Leu Lys Arg 
                165                 170                 175     


Val Thr Thr Thr Arg Leu Asp Ala Pro Ser Gln Ile Glu Val Lys Asp 
            180                 185                 190         


Val Thr Asp Thr Thr Ala Leu Ile Thr Trp Phe Lys Pro Leu Ala Glu 
        195                 200                 205             


Ile Asp Gly Ile Glu Leu Thr Tyr Gly Ile Lys Asp Val Pro Gly Asp 
    210                 215                 220                 


Arg Thr Thr Ile Asp Leu Thr Glu Asp Glu Asn Gln Tyr Ser Ile Gly 
225                 230                 235                 240 


Asn Leu Lys Pro Asp Thr Glu Tyr Glu Val Ser Leu Ile Ser Arg Arg 
                245                 250                 255     


Gly Asp Met Ser Ser Asn Pro Ala Lys Glu Thr Phe Thr Thr Gly Leu 
            260                 265                 270         


Asp Ala Pro Arg Asn Leu Arg Arg Val Ser Gln Thr Asp Asn Ser Ile 
        275                 280                 285             


Thr Leu Glu Trp Arg Asn Gly Lys Ala Ala Ile Asp Ser Tyr Arg Ile 
    290                 295                 300                 


Lys Tyr Ala Pro Ile Ser Gly Gly Asp His Ala Glu Val Asp Val Pro 
305                 310                 315                 320 


Lys Ser Gln Gln Ala Thr Thr Lys Thr Thr Leu Thr Gly Leu Arg Pro 
                325                 330                 335     


Gly Thr Glu Tyr Gly Ile Gly Val Ser Ala Val Lys Glu Asp Lys Glu 
            340                 345                 350         


Ser Asn Pro Ala Thr Ile Asn Ala Ala Thr Glu Leu Asp Thr Pro Lys 
        355                 360                 365             


Asp Leu Gln Val Ser Glu Thr Ala Glu Thr Ser Leu Thr Leu Leu Trp 
    370                 375                 380                 


Lys Thr Pro Leu Ala Lys Phe Asp Arg Tyr Arg Leu Asn Tyr Ser Leu 
385                 390                 395                 400 


Pro Thr Gly Gln Trp Val Gly Val Gln Leu Pro Arg Asn Thr Thr Ser 
                405                 410                 415     


Tyr Val Leu Arg Gly Leu Glu Pro Gly Gln Glu Tyr Asn Val Leu Leu 
            420                 425                 430         


Thr Ala Glu Lys Gly Arg His Lys Ser Lys Pro Ala Arg Val Lys Ala 
        435                 440                 445             


Ser Thr Glu Gln Ala Pro Glu Leu Glu Asn Leu Thr Val Thr Glu Val 
    450                 455                 460                 


Gly Trp Asp Gly Leu Arg Leu Asn Trp Thr Ala Ala Asp Gln Ala Tyr 
465                 470                 475                 480 


Glu His Phe Ile Ile Gln Val Gln Glu Ala Asn Lys Val Glu Ala Ala 
                485                 490                 495     


Arg Asn Leu Thr Val Pro Gly Ser Leu Arg Ala Val Asp Ile Pro Gly 
            500                 505                 510         


Leu Lys Ala Ala Thr Pro Tyr Thr Val Ser Ile Tyr Gly Val Ile Gln 
        515                 520                 525             


Gly Tyr Arg Thr Pro Val Leu Ser Ala Glu Ala Ser Thr Gly Glu Thr 
    530                 535                 540                 


Pro Asn Leu Gly Glu Val Val Val Ala Glu Val Gly Trp Asp Ala Leu 
545                 550                 555                 560 


Lys Leu Asn Trp Thr Ala Pro Glu Gly Ala Tyr Glu Tyr Phe Phe Ile 
                565                 570                 575     


Gln Val Gln Glu Ala Asp Thr Val Glu Ala Ala Gln Asn Leu Thr Val 
            580                 585                 590         


Pro Gly Gly Leu Arg Ser Thr Asp Leu Pro Gly Leu Lys Ala Ala Thr 
        595                 600                 605             


His Tyr Thr Ile Thr Ile Arg Gly Val Thr Gln Asp Phe Ser Thr Thr 
    610                 615                 620                 


Pro Leu Ser Val Glu Val Leu Thr Glu Glu Val Pro Asp Met Gly Asn 
625                 630                 635                 640 


Leu Thr Val Thr Glu Val Ser Trp Asp Ala Leu Arg Leu Asn Trp Thr 
                645                 650                 655     


Thr Pro Asp Gly Thr Tyr Asp Gln Phe Thr Ile Gln Val Gln Glu Ala 
            660                 665                 670         


Asp Gln Val Glu Glu Ala His Asn Leu Thr Val Pro Gly Ser Leu Arg 
        675                 680                 685             


Ser Met Glu Ile Pro Gly Leu Arg Ala Gly Thr Pro Tyr Thr Val Thr 
    690                 695                 700                 


Leu His Gly Glu Val Arg Gly His Ser Thr Arg Pro Leu Ala Val Glu 
705                 710                 715                 720 


Val Val Thr Glu Asp Leu Pro Gln Leu Gly Asp Leu Ala Val Ser Glu 
                725                 730                 735     


Val Gly Trp Asp Gly Leu Arg Leu Asn Trp Thr Ala Ala Asp Asn Ala 
            740                 745                 750         


Tyr Glu His Phe Val Ile Gln Val Gln Glu Val Asn Lys Val Glu Ala 
        755                 760                 765             


Ala Gln Asn Leu Thr Leu Pro Gly Ser Leu Arg Ala Val Asp Ile Pro 
    770                 775                 780                 


Gly Leu Glu Ala Ala Thr Pro Tyr Arg Val Ser Ile Tyr Gly Val Ile 
785                 790                 795                 800 


Arg Gly Tyr Arg Thr Pro Val Leu Ser Ala Glu Ala Ser Thr Ala Lys 
                805                 810                 815     


Glu Pro Glu Ile Gly Asn Leu Asn Val Ser Asp Ile Thr Pro Glu Ser 
            820                 825                 830         


Phe Asn Leu Ser Trp Met Ala Thr Asp Gly Ile Phe Glu Thr Phe Thr 
        835                 840                 845             


Ile Glu Ile Ile Asp Ser Asn Arg Leu Leu Glu Thr Val Glu Tyr Asn 
    850                 855                 860                 


Ile Ser Gly Ala Glu Arg Thr Ala His Ile Ser Gly Leu Pro Pro Ser 
865                 870                 875                 880 


Thr Asp Phe Ile Val Tyr Leu Ser Gly Leu Ala Pro Ser Ile Arg Thr 
                885                 890                 895     


Lys Thr Ile Ser Ala Thr Ala Thr Thr Glu Ala Leu Pro Leu Leu Glu 
            900                 905                 910         


Asn Leu Thr Ile Ser Asp Ile Asn Pro Tyr Gly Phe Thr Val Ser Trp 
        915                 920                 925             


Met Ala Ser Glu Asn Ala Phe Asp Ser Phe Leu Val Thr Val Val Asp 
    930                 935                 940                 


Ser Gly Lys Leu Leu Asp Pro Gln Glu Phe Thr Leu Ser Gly Thr Gln 
945                 950                 955                 960 


Arg Lys Leu Glu Leu Arg Gly Leu Ile Thr Gly Ile Gly Tyr Glu Val 
                965                 970                 975     


Met Val Ser Gly Phe Thr Gln Gly His Gln Thr Lys Pro Leu Arg Ala 
            980                 985                 990         


Glu Ile Val Thr Glu Ala Glu Pro  Glu Val Asp Asn Leu  Leu Val Ser 
        995                 1000                 1005             


Asp Ala  Thr Pro Asp Gly Phe  Arg Leu Ser Trp Thr  Ala Asp Glu 
    1010                 1015                 1020             


Gly Val  Phe Asp Asn Phe Val  Leu Lys Ile Arg Asp  Thr Lys Lys 
    1025                 1030                 1035             


Gln Ser  Glu Pro Leu Glu Ile  Thr Leu Leu Ala Pro  Glu Arg Thr 
    1040                 1045                 1050             


Arg Asp  Leu Thr Gly Leu Arg  Glu Ala Thr Glu Tyr  Glu Ile Glu 
    1055                 1060                 1065             


Leu Tyr  Gly Ile Ser Lys Gly  Arg Arg Ser Gln Thr  Val Ser Ala 
    1070                 1075                 1080             


Ile Ala  Thr Thr Ala Met Gly  Ser Pro Lys Glu Val  Ile Phe Ser 
    1085                 1090                 1095             


Asp Ile  Thr Glu Asn Ser Ala  Thr Val Ser Trp Arg  Ala Pro Thr 
    1100                 1105                 1110             


Ala Gln  Val Glu Ser Phe Arg  Ile Thr Tyr Val Pro  Ile Thr Gly 
    1115                 1120                 1125             


Gly Thr  Pro Ser Met Val Thr  Val Asp Gly Thr Lys  Thr Gln Thr 
    1130                 1135                 1140             


Arg Leu  Val Lys Leu Ile Pro  Gly Val Glu Tyr Leu  Val Ser Ile 
    1145                 1150                 1155             


Ile Ala  Met Lys Gly Phe Glu  Glu Ser Glu Pro Val  Ser Gly Ser 
    1160                 1165                 1170             


Phe Thr  Thr Ala Leu Asp Gly  Pro Ser Gly Leu Val  Thr Ala Asn 
    1175                 1180                 1185             


Ile Thr  Asp Ser Glu Ala Leu  Ala Arg Trp Gln Pro  Ala Ile Ala 
    1190                 1195                 1200             


Thr Val  Asp Ser Tyr Val Ile  Ser Tyr Thr Gly Glu  Lys Val Pro 
    1205                 1210                 1215             


Glu Ile  Thr Arg Thr Val Ser  Gly Asn Thr Val Glu  Tyr Ala Leu 
    1220                 1225                 1230             


Thr Asp  Leu Glu Pro Ala Thr  Glu Tyr Thr Leu Arg  Ile Phe Ala 
    1235                 1240                 1245             


Glu Lys  Gly Pro Gln Lys Ser  Ser Thr Ile Thr Ala  Lys Phe Thr 
    1250                 1255                 1260             


Thr Asp  Leu Asp Ser Pro Arg  Asp Leu Thr Ala Thr  Glu Val Gln 
    1265                 1270                 1275             


Ser Glu  Thr Ala Leu Leu Thr  Trp Arg Pro Pro Arg  Ala Ser Val 
    1280                 1285                 1290             


Thr Gly  Tyr Leu Leu Val Tyr  Glu Ser Val Asp Gly  Thr Val Lys 
    1295                 1300                 1305             


Glu Val  Ile Val Gly Pro Asp  Thr Thr Ser Tyr Ser  Leu Ala Asp 
    1310                 1315                 1320             


Leu Ser  Pro Ser Thr His Tyr  Thr Ala Lys Ile Gln  Ala Leu Asn 
    1325                 1330                 1335             


Gly Pro  Leu Arg Ser Asn Met  Ile Gln Thr Ile Phe  Thr Thr 
    1340                 1345                 1350         


<210>  147
<211>  228
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Human Tenascin-C FBG domain

<400>  147

Ile Gly Leu Leu Tyr Pro Phe Pro Lys Asp Cys Ser Gln Ala Met Leu 
1               5                   10                  15      


Asn Gly Asp Thr Thr Ser Gly Leu Tyr Thr Ile Tyr Leu Asn Gly Asp 
            20                  25                  30          


Lys Ala Gln Ala Leu Glu Val Phe Cys Asp Met Thr Ser Asp Gly Gly 
        35                  40                  45              


Gly Trp Ile Val Phe Leu Arg Arg Lys Asn Gly Arg Glu Asn Phe Tyr 
    50                  55                  60                  


Gln Asn Trp Lys Ala Tyr Ala Ala Gly Phe Gly Asp Arg Arg Glu Glu 
65                  70                  75                  80  


Phe Trp Leu Gly Leu Asp Asn Leu Asn Lys Ile Thr Ala Gln Gly Gln 
                85                  90                  95      


Tyr Glu Leu Arg Val Asp Leu Arg Asp His Gly Glu Thr Ala Phe Ala 
            100                 105                 110         


Val Tyr Asp Lys Phe Ser Val Gly Asp Ala Lys Thr Arg Tyr Lys Leu 
        115                 120                 125             


Lys Val Glu Gly Tyr Ser Gly Thr Ala Gly Asp Ser Met Ala Tyr His 
    130                 135                 140                 


Asn Gly Arg Ser Phe Ser Thr Phe Asp Lys Asp Thr Asp Ser Ala Ile 
145                 150                 155                 160 


Thr Asn Cys Ala Leu Ser Tyr Lys Gly Ala Phe Trp Tyr Arg Asn Cys 
                165                 170                 175     


His Arg Val Asn Leu Met Gly Arg Tyr Gly Asp Asn Asn His Ser Gln 
            180                 185                 190         


Gly Val Asn Trp Phe His Trp Lys Gly His Glu His Ser Ile Gln Phe 
        195                 200                 205             


Ala Glu Met Lys Leu Arg Pro Ser Asn Phe Arg Asn Leu Glu Gly Arg 
    210                 215                 220                 


Arg Lys Arg Ala 
225             


<210>  148
<211>  7616
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Human Tenascin-C nucleotide sequence

<400>  148
attacagagg aaggagctcg ctatataagc cagccaaagt tggctgcacc ggccacagcc       60

tgcctactgt cacccgcctc tcccgcgcgc agatacacgc ccccgcctcc gtgggcacaa      120

aggcagcgct gctggggaac tcgggggaac gcgcacgtgg gaaccgccgc agctccacac      180

tccaggtact tcttccaagg acctaggtct ctcgcccatc ggaaagaaaa taattctttc      240

aagaagatca gggacaactg atttgaagtc tactctgtgc ttctaaatcc ccaattctgc      300

tgaaagtgag ataccctaga gccctagagc cccagcagca cccagccaaa cccacctcca      360

ccatgggggc catgactcag ctgttggcag gtgtctttct tgctttcctt gccctcgcta      420

ccgaaggtgg ggtcctcaag aaagtcatcc ggcacaagcg acagagtggg gtgaacgcca      480

ccctgccaga agagaaccag ccagtggtgt ttaaccacgt ttacaacatc aagctgccag      540

tgggatccca gtgttcggtg gatctggagt cagccagtgg ggagaaagac ctggcaccgc      600

cttcagagcc cagcgaaagc tttcaggagc acacagtgga tggggaaaac cagattgtct      660

tcacacatcg catcaacatc ccccgccggg cctgtggctg tgccgcagcc cctgatgtta      720

aggagctgct gagcagactg gaggagctgg agaacctggt gtcttccctg agggagcaat      780

gtactgcagg agcaggctgc tgtctccagc ctgccacagg ccgcttggac accaggccct      840

tctgtagcgg tcggggcaac ttcagcactg aaggatgtgg ctgtgtctgc gaacctggct      900

ggaaaggccc caactgctct gagcccgaat gtccaggcaa ctgtcacctt cgaggccggt      960

gcattgatgg gcagtgcatc tgtgacgacg gcttcacggg cgaggactgc agccagctgg     1020

cttgccccag cgactgcaat gaccagggca agtgcgtaaa tggagtctgc atctgtttcg     1080

aaggctacgc cggggctgac tgcagccgtg aaatctgccc agtgccctgc agtgaggagc     1140

acggcacatg tgtagatggc ttgtgtgtgt gccacgatgg ctttgcaggc gatgactgca     1200

acaagcctct gtgtctcaac aattgctaca accgtggacg atgcgtggag aatgagtgcg     1260

tgtgtgatga gggtttcacg ggcgaagact gcagtgagct catctgcccc aatgactgct     1320

tcgaccgggg ccgctgcatc aatggcacct gctactgcga agaaggcttc acaggtgaag     1380

actgcgggaa acccacctgc ccacatgcct gccacaccca gggccggtgt gaggaggggc     1440

agtgtgtatg tgatgagggc tttgccggtg tggactgcag cgagaagagg tgtcctgctg     1500

actgtcacaa tcgtggccgc tgtgtagacg ggcggtgtga gtgtgatgat ggtttcactg     1560

gagctgactg tggggagctc aagtgtccca atggctgcag tggccatggc cgctgtgtca     1620

atgggcagtg tgtgtgtgat gagggctata ctggggagga ctgcagccag ctacggtgcc     1680

ccaatgactg tcacagtcgg ggccgctgtg tcgagggcaa atgtgtatgt gagcaaggct     1740

tcaagggcta tgactgcagt gacatgagct gccctaatga ctgtcaccag cacggccgct     1800

gtgtgaatgg catgtgtgtt tgtgatgacg gctacacagg ggaagactgc cgggatcgcc     1860

aatgccccag ggactgcagc aacaggggcc tctgtgtgga cggacagtgc gtctgtgagg     1920

acggcttcac cggccctgac tgtgcagaac tctcctgtcc aaatgactgc catggccagg     1980

gtcgctgtgt gaatgggcag tgcgtgtgcc atgaaggatt tatgggcaaa gactgcaagg     2040

agcaaagatg tcccagtgac tgtcatggcc agggccgctg cgtggacggc cagtgcatct     2100

gccacgaggg cttcacaggc ctggactgtg gccagcactc ctgccccagt gactgcaaca     2160

acttaggaca atgcgtctcg ggccgctgca tctgcaacga gggctacagc ggagaagact     2220

gctcagaggt gtctcctccc aaagacctcg ttgtgacaga agtgacggaa gagacggtca     2280

acctggcctg ggacaatgag atgcgggtca cagagtacct tgtcgtgtac acgcccaccc     2340

acgagggtgg tctggaaatg cagttccgtg tgcctgggga ccagacgtcc accatcatcc     2400

aggagctgga gcctggtgtg gagtacttta tccgtgtatt tgccatcctg gagaacaaga     2460

agagcattcc tgtcagcgcc agggtggcca cgtacttacc tgcacctgaa ggcctgaaat     2520

tcaagtccat caaggagaca tctgtggaag tggagtggga tcctctagac attgcttttg     2580

aaacctggga gatcatcttc cggaatatga ataaagaaga tgagggagag atcaccaaaa     2640

gcctgaggag gccagagacc tcttaccggc aaactggtct agctcctggg caagagtatg     2700

agatatctct gcacatagtg aaaaacaata cccggggccc tggcctgaag agggtgacca     2760

ccacacgctt ggatgccccc agccagatcg aggtgaaaga tgtcacagac accactgcct     2820

tgatcacctg gttcaagccc ctggctgaga tcgatggcat tgagctgacc tacggcatca     2880

aagacgtgcc aggagaccgt accaccatcg atctcacaga ggacgagaac cagtactcca     2940

tcgggaacct gaagcctgac actgagtacg aggtgtccct catctcccgc agaggtgaca     3000

tgtcaagcaa cccagccaaa gagaccttca caacaggcct cgatgctccc aggaatcttc     3060

gacgtgtttc ccagacagat aacagcatca ccctggaatg gaggaatggc aaggcagcta     3120

ttgacagtta cagaattaag tatgccccca tctctggagg ggaccacgct gaggttgatg     3180

ttccaaagag ccaacaagcc acaaccaaaa ccacactcac aggtctgagg ccgggaactg     3240

aatatgggat tggagtttct gctgtgaagg aagacaagga gagcaatcca gcgaccatca     3300

acgcagccac agagttggac acgcccaagg accttcaggt ttctgaaact gcagagacca     3360

gcctgaccct gctctggaag acaccgttgg ccaaatttga ccgctaccgc ctcaattaca     3420

gtctccccac aggccagtgg gtgggagtgc agcttccaag aaacaccact tcctatgtcc     3480

tgagaggcct ggaaccagga caggagtaca atgtcctcct gacagccgag aaaggcagac     3540

acaagagcaa gcccgcacgt gtgaaggcat ccactgaaca agcccctgag ctggaaaacc     3600

tcaccgtgac tgaggttggc tgggatggcc tcagactcaa ctggaccgca gctgaccagg     3660

cctatgagca ctttatcatt caggtgcagg aggccaacaa ggtggaggca gctcggaacc     3720

tcaccgtgcc tggcagcctt cgggctgtgg acataccggg cctcaaggct gctacgcctt     3780

atacagtctc catctatggg gtgatccagg gctatagaac accagtgctc tctgctgagg     3840

cctccacagg ggaaactccc aatttgggag aggtcgtggt ggccgaggtg ggctgggatg     3900

ccctcaaact caactggact gctccagaag gggcctatga gtactttttc attcaggtgc     3960

aggaggctga cacagtagag gcagcccaga acctcaccgt cccaggagga ctgaggtcca     4020

cagacctgcc tgggctcaaa gcagccactc attataccat caccatccgc ggggtcactc     4080

aggacttcag cacaacccct ctctctgttg aagtcttgac agaggaggtt ccagatatgg     4140

gaaacctcac agtgaccgag gttagctggg atgctctcag actgaactgg accacgccag     4200

atggaaccta tgaccagttt actattcagg tccaggaggc tgaccaggtg gaagaggctc     4260

acaatctcac ggttcctggc agcctgcgtt ccatggaaat cccaggcctc agggctggca     4320

ctccttacac agtcaccctg cacggcgagg tcaggggcca cagcactcga ccccttgctg     4380

tagaggtcgt cacagaggat ctcccacagc tgggagattt agccgtgtct gaggttggct     4440

gggatggcct cagactcaac tggaccgcag ctgacaatgc ctatgagcac tttgtcattc     4500

aggtgcagga ggtcaacaaa gtggaggcag cccagaacct cacgttgcct ggcagcctca     4560

gggctgtgga catcccgggc ctcgaggctg ccacgcctta tagagtctcc atctatgggg     4620

tgatccgggg ctatagaaca ccagtactct ctgctgaggc ctccacagcc aaagaacctg     4680

aaattggaaa cttaaatgtt tctgacataa ctcccgagag cttcaatctc tcctggatgg     4740

ctaccgatgg gatcttcgag acctttacca ttgaaattat tgattccaat aggttgctgg     4800

agactgtgga atataatatc tctggtgctg aacgaactgc ccatatctca gggctacccc     4860

ctagtactga ttttattgtc tacctctctg gacttgctcc cagcatccgg accaaaacca     4920

tcagtgccac agccacgaca gaggccctgc cccttctgga aaacctaacc atttccgaca     4980

ttaatcccta cgggttcaca gtttcctgga tggcatcgga gaatgccttt gacagctttc     5040

tagtaacggt ggtggattct gggaagctgc tggaccccca ggaattcaca ctttcaggaa     5100

cccagaggaa gctggagctt agaggcctca taactggcat tggctatgag gttatggtct     5160

ctggcttcac ccaagggcat caaaccaagc ccttgagggc tgagattgtt acagaagccg     5220

aaccggaagt tgacaacctt ctggtttcag atgccacccc agacggtttc cgtctgtcct     5280

ggacagctga tgaaggggtc ttcgacaatt ttgttctcaa aatcagagat accaaaaagc     5340

agtctgagcc actggaaata accctacttg cccccgaacg taccagggac ataacaggtc     5400

tcagagaggc tactgaatac gaaattgaac tctatggaat aagcaaagga aggcgatccc     5460

agacagtcag tgctatagca acaacagcca tgggctcccc aaaggaagtc attttctcag     5520

acatcactga aaattcggct actgtcagct ggagggcacc cacagcccaa gtggagagct     5580

tccggattac ctatgtgccc attacaggag gtacaccctc catggtaact gtggacggaa     5640

ccaagactca gaccaggctg gtgaaactca tacctggcgt ggagtacctt gtcagcatca     5700

tcgccatgaa gggctttgag gaaagtgaac ctgtctcagg gtcattcacc acagctctgg     5760

atggcccatc tggcctggtg acagccaaca tcactgactc agaagccttg gccaggtggc     5820

agccagccat tgccactgtg gacagttatg tcatctccta cacaggcgag aaagtgccag     5880

aaattacacg cacggtgtcc gggaacacag tggagtatgc tctgaccgac ctcgagcctg     5940

ccacggaata cacactgaga atctttgcag agaaagggcc ccagaagagc tcaaccatca     6000

ctgccaagtt cacaacagac ctcgattctc caagagactt gactgctact gaggttcagt     6060

cggaaactgc cctccttacc tggcgacccc cccgggcatc agtcaccggt tacctgctgg     6120

tctatgaatc agtggatggc acagtcaagg aagtcattgt gggtccagat accacctcct     6180

acagcctggc agacctgagc ccatccaccc actacacagc caagatccag gcactcaatg     6240

ggcccctgag gagcaatatg atccagacca tcttcaccac aattggactc ctgtacccct     6300

tccccaagga ctgctcccaa gcaatgctga atggagacac gacctctggc ctctacacca     6360

tttatctgaa tggtgataag gctgaggcgc tggaagtctt ctgtgacatg acctctgatg     6420

ggggtggatg gattgtgttc ctgagacgca aaaacggacg cgagaacttc taccaaaact     6480

ggaaggcata tgctgctgga tttggggacc gcagagaaga attctggctt gggctggaca     6540

acctgaacaa aatcacagcc caggggcagt acgagctccg ggtggacctg cgggaccatg     6600

gggagacagc ctttgctgtc tatgacaagt tcagcgtggg agatgccaag actcgctaca     6660

agctgaaggt ggaggggtac agtgggacag caggtgactc catggcctac cacaatggca     6720

gatccttctc cacctttgac aaggacacag attcagccat caccaactgt gctctgtcct     6780

acaaaggggc tttctggtac aggaactgtc accgtgtcaa cctgatgggg agatatgggg     6840

acaataacca cagtcagggc gttaactggt tccactggaa gggccacgaa cactcaatcc     6900

agtttgctga gatgaagctg agaccaagca acttcagaaa tcttgaaggc aggcgcaaac     6960

gggcataaat tccagggacc actgggtgag agaggaataa ggcccagagc gaggaaagga     7020

ttttaccaaa gcatcaatac aaccagccca accatcggtc cacacctggg catttggtga     7080

gagtcaaagc tgaccatgga tccctggggc caacggcaac agcatgggcc tcacctcctc     7140

tgtgatttct ttctttgcac caaagacatc agtctccaac atgtttctgt tttgttgttt     7200

gattcagcaa aaatctccca gtgacaacat cgcaatagtt ttttacttct cttaggtggc     7260

tctgggaatg ggagaggggt aggatgtaca ggggtagttt gttttagaac cagccgtatt     7320

ttacatgaag ctgtataatt aattgtcatt atttttgtta gcaaagatta aatgtgtcat     7380

tggaagccat cccttttttt acatttcata caacagaaac cagaaaagca atactgtttc     7440

cattttaagg atatgattaa tattattaat ataataatga tgatgatgat gatgaaaact     7500

aaggattttt caagagatct ttctttccaa aacatttctg gacagtacct gattgtattt     7560

tttttttaaa taaaagcaca agtacttttg agtttgttaa aaaaaaaaaa aaaaaa         7616


<210>  149
<211>  22
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Human FBG-X primer minus

<400>  149
ggtacctcgc gaatgcatct ag                                                22


<210>  150
<211>  58
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Human FBG-X plus

<400>  150
ttttttccat ggcccagatt ggactcctgt accccttccc caaagattgc tctcaggc         58


<210>  151
<211>  22
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Mouse FBG-X primer minus

<400>  151
ggtacctcgc gaatgcatct ag                                                22


<210>  152
<211>  56
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Mouse FBG-X primer plus

<400>  152
ttttttccat ggcccagatt ggactcctgt accccttccc tcgcgactgc tcacag           56


<210>  153
<211>  53
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Human X-FBG primer minus

<400>  153
ttttttggat cccatcatca tcaccatcac ttccccaaag attgctctca ggc              53


<210>  154
<211>  71
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Human X-FBG primer plus

<400>  154
ttttttggat cccatcatca tcaccatcac attggactcc tgtacccctt ccccaaagat       60

tgctctcagg c                                                            71


<210>  155
<211>  51
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Mouse X-FBG primer minus

<400>  155
ttttttggat cccatcatca tcaccatcac ttccctcgcg actgctcaca g                51


<210>  156
<211>  69
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Mouse X-FBG primer plus

<400>  156
ttttttggat cccatcatca tcaccatcac attggactcc tgtacccctt ccctcgcgac       60

tgctcacag                                                               69


<210>  157
<211>  39
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  BamHI-His6-HindIII primer

<400>  157
ttttttggat cccatcatca tcaccatcac taataaaag                              39


<210>  158
<211>  40
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Human His-FBG primer plus

<400>  158
ttttttctcg agcatcatca tcaccatcac attggactcc                             40


<210>  159
<211>  40
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Mouse His-FBG primer plus

<400>  159
ttttttctcg agcatcatca tcaccatcac attggactcc                             40


<210>  160
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Hinge linker

<400>  160

Asp Lys Thr His Thr Cys Ala Ala 
1               5               


<210>  161
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Hinge linker

<400>  161

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 
1               5                   10      


<210>  162
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Hinge linker

<400>  162

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Thr Cys Pro Pro Cys 
1               5                   10                  15      


Pro Ala 
        


<210>  163
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Hinge linker

<400>  163

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Thr Cys Pro Pro Cys 
1               5                   10                  15      


Pro Ala Thr Cys Pro Pro Cys Pro Ala 
            20                  25  


<210>  164
<211>  30
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Hinge linker

<400>  164

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Gly Lys Pro Thr Leu 
1               5                   10                  15      


Tyr Asn Ser Leu Val Met Ser Asp Thr Ala Gly Thr Cys Tyr 
            20                  25                  30  


<210>  165
<211>  31
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Hinge linker

<400>  165

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Gly Lys Pro Thr His 
1               5                   10                  15      


Val Asn Val Ser Val Val Met Ala Glu Val Asp Gly Thr Cys Tyr 
            20                  25                  30      


<210>  166
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Hinge linker

<400>  166

Asp Lys Thr His Thr Cys Cys Val Glu Cys Pro Pro Cys Pro Ala 
1               5                   10                  15  


<210>  167
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Hinge linker

<400>  167

Asp Lys Thr His Thr Cys Pro Arg Cys Pro Glu Pro Lys Ser Cys Asp 
1               5                   10                  15      


Thr Pro Pro Pro Cys Pro Arg Cys Pro Ala 
            20                  25      


<210>  168
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Hinge linker

<400>  168

Asp Lys Thr His Thr Cys Pro Ser Cys Pro Ala 
1               5                   10      


<210>  169
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Flexible linker

<400>  169

Ser Gly Gly Gly Gly Ser Glu 
1               5           


<210>  170
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Flexible linker

<400>  170

Asp Lys Thr His Thr Ser 
1               5       


<210>  171
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Flexible linker

<400>  171

Ser Gly Gly Gly Gly Ser 
1               5       


<210>  172
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Flexible linker

<400>  172

Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 
1               5                   10      


<210>  173
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Flexible linker

<400>  173

Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 
1               5                   10                  15      


<210>  174
<211>  21
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Flexible linker

<400>  174

Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 
1               5                   10                  15      


Gly Gly Gly Gly Ser 
            20      


<210>  175
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Flexible linker

<400>  175

Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 
1               5                   10                  15      


Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 
            20                  25      


<210>  176
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Flexible linker

<400>  176

Ala Ala Ala Gly Ser Gly Gly Ala Ser Ala Ser 
1               5                   10      


<210>  177
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Flexible linker


<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa can be any naturally occurring amino acid

<400>  177

Ala Ala Ala Gly Ser Gly Xaa Gly Gly Gly Ser Gly Ala Ser Ala Ser 
1               5                   10                  15      


<210>  178
<211>  21
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Flexible linker


<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa can be any naturally occurring amino acid

<220>
<221>  misc_feature
<222>  (12)..(12)
<223>  Xaa can be any naturally occurring amino acid

<400>  178

Ala Ala Ala Gly Ser Gly Xaa Gly Gly Gly Ser Xaa Gly Gly Gly Ser 
1               5                   10                  15      


Gly Ala Ser Ala Ser 
            20      


<210>  179
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Flexible linker


<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa can be any naturally occurring amino acid

<220>
<221>  misc_feature
<222>  (12)..(12)
<223>  Xaa can be any naturally occurring amino acid

<220>
<221>  misc_feature
<222>  (17)..(17)
<223>  Xaa can be any naturally occurring amino acid

<400>  179

Ala Ala Ala Gly Ser Gly Xaa Gly Gly Gly Ser Xaa Gly Gly Gly Ser 
1               5                   10                  15      


Xaa Gly Gly Gly Ser Gly Ala Ser Ala Ser 
            20                  25      


<210>  180
<211>  31
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Flexible linker


<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa can be any naturally occurring amino acid

<220>
<221>  misc_feature
<222>  (12)..(12)
<223>  Xaa can be any naturally occurring amino acid

<220>
<221>  misc_feature
<222>  (17)..(17)
<223>  Xaa can be any naturally occurring amino acid

<220>
<221>  misc_feature
<222>  (22)..(22)
<223>  Xaa can be any naturally occurring amino acid

<400>  180

Ala Ala Ala Gly Ser Gly Xaa Gly Gly Gly Ser Xaa Gly Gly Gly Ser 
1               5                   10                  15      


Xaa Gly Gly Gly Ser Xaa Gly Gly Gly Ser Gly Ala Ser Ala Ser 
            20                  25                  30      


<210>  181
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Flexible linker


<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa can be any naturally occurring amino acid

<400>  181

Ala Ala Ala Gly Ser Gly Xaa Ser Gly Ala Ser Ala Ser 
1               5                   10              


<210>  182
<211>  28
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Flexible linker

<400>  182

Pro Gly Gly Asn Arg Gly Thr Thr Thr Thr Arg Arg Pro Ala Thr Thr 
1               5                   10                  15      


Thr Gly Ser Ser Pro Gly Pro Thr Gln Ser His Tyr 
            20                  25              


<210>  183
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Flexible linker

<400>  183

Ala Thr Thr Thr Gly Ser Ser Pro Gly Pro Thr 
1               5                   10      


<210>  184
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Flexible linker

<400>  184

Ala Thr Thr Thr Gly Ser 
1               5       


<210>  185
<211>  21
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Flexible linker

<400>  185

Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Ser Pro Pro Ser Lys Glu 
1               5                   10                  15      


Ser His Lys Ser Pro 
            20      


<210>  186
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Flexible linker

<400>  186

Gly Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp 
1               5                   10                  15  


<210>  187
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Flexible linker

<400>  187

Gly Gly Gly Gly Ile Ala Pro Ser Met Val Gly Gly Gly Gly Ser 
1               5                   10                  15  


<210>  188
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Flexible linker

<400>  188

Gly Gly Gly Gly Lys Val Glu Gly Ala Gly Gly Gly Gly Gly Ser 
1               5                   10                  15  


<210>  189
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Flexible linker

<400>  189

Gly Gly Gly Gly Ser Met Lys Ser His Asp Gly Gly Gly Gly Ser 
1               5                   10                  15  


<210>  190
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Flexible linker

<400>  190

Gly Gly Gly Gly Asn Leu Ile Thr Ile Val Gly Gly Gly Gly Ser 
1               5                   10                  15  


<210>  191
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Flexible linker

<400>  191

Gly Gly Gly Gly Val Val Pro Ser Leu Pro Gly Gly Gly Gly Ser 
1               5                   10                  15  


<210>  192
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Flexible linker

<400>  192

Gly Gly Glu Lys Ser Ile Pro Gly Gly Gly Gly Ser 
1               5                   10          


<210>  193
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Flexible linker

<400>  193

Arg Pro Leu Ser Tyr Arg Pro Pro Phe Pro Phe Gly Phe Pro Ser Val 
1               5                   10                  15      


Arg Pro 
        


<210>  194
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Flexible linker

<400>  194

Tyr Pro Arg Ser Ile Tyr Ile Arg Arg Arg His Pro Ser Pro Ser Leu 
1               5                   10                  15      


Thr Thr 
        


<210>  195
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Flexible linker

<400>  195

Thr Pro Ser His Leu Ser His Ile Leu Pro Ser Phe Gly Leu Pro Thr 
1               5                   10                  15      


Phe Asn 
        


<210>  196
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Flexible linker

<400>  196

Arg Pro Val Ser Pro Phe Thr Phe Pro Arg Leu Ser Asn Ser Trp Leu 
1               5                   10                  15      


Pro Ala 
        


<210>  197
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Flexible linker

<400>  197

Ser Pro Ala Ala His Phe Pro Arg Ser Ile Pro Arg Pro Gly Pro Ile 
1               5                   10                  15      


Arg Thr 
        


<210>  198
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Flexible linker

<400>  198

Ala Pro Gly Pro Ser Ala Pro Ser His Arg Ser Leu Pro Ser Arg Ala 
1               5                   10                  15      


Phe Gly 
        


<210>  199
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Flexible linker

<400>  199

Pro Arg Asn Ser Ile His Phe Leu His Pro Leu Leu Val Ala Pro Leu 
1               5                   10                  15      


Gly Ala 
        


<210>  200
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Flexible linker

<400>  200

Met Pro Ser Leu Ser Gly Val Leu Gln Val Arg Tyr Leu Ser Pro Pro 
1               5                   10                  15      


Asp Leu 
        


<210>  201
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Flexible linker

<400>  201

Ser Pro Gln Tyr Pro Ser Pro Leu Thr Leu Thr Leu Pro Pro His Pro 
1               5                   10                  15      


Ser Leu 
        


<210>  202
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Flexible linker

<400>  202

Asn Pro Ser Leu Asn Pro Pro Ser Tyr Leu His Arg Ala Pro Ser Arg 
1               5                   10                  15      


Ile Ser 
        


<210>  203
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Flexible linker

<400>  203

Leu Pro Trp Arg Thr Ser Leu Leu Pro Ser Leu Pro Leu Arg Arg Arg 
1               5                   10                  15      


Pro 
    


<210>  204
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Flexible linker

<400>  204

Pro Pro Leu Phe Ala Lys Gly Pro Val Gly Leu Leu Ser Arg Ser Phe 
1               5                   10                  15      


Pro Pro 
        


<210>  205
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Flexible linker

<400>  205

Val Pro Pro Ala Pro Val Val Ser Leu Arg Ser Ala His Ala Arg Pro 
1               5                   10                  15      


Pro Tyr 
        


<210>  206
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Flexible linker

<400>  206

Leu Arg Pro Thr Pro Pro Arg Val Arg Ser Tyr Thr Cys Cys Pro Thr 
1               5                   10                  15      


Pro 
    


<210>  207
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Flexible linker

<400>  207

Pro Asn Val Ala His Val Leu Pro Leu Leu Thr Val Pro Trp Asp Asn 
1               5                   10                  15      


Leu Arg 
        


<210>  208
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Flexible linker

<400>  208

Cys Asn Pro Leu Leu Pro Leu Cys Ala Arg Ser Pro Ala Val Arg Thr 
1               5                   10                  15      


Phe Pro 
        


<210>  209
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Rigid linker

<400>  209

Gly Ala Pro Ala Pro Ala Ala Pro Ala Pro Ala 
1               5                   10      


<210>  210
<211>  4
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Rigid linker

<400>  210

Pro Pro Pro Pro 
1               


